Citation Report
List of articles citing

Differentiation and reversal of malignant changes in colon cancer through PPARgamma

DOI: 10.1038/2030
Nature Medicine, 1998, 4, 1046-52.

#	Paper	IF	Citations
896	Telmisartan is a potent target for prevention and treatment in human prostate cancer. **1994**, 20, 295		4
895	PPARgamma and colorectal carcinoma: conflicts in a nuclear family. *Nature Medicine*, **1998**, 4, 1004-5	50.5	43
894	A gut check for PPARgamma. **1998**, 115, 1283-5		9
893	Role and Regulation of PPARγ During Adipogenesis. **1999**, 77, 9		5
892	Effect of the retinoid X receptor-selective ligand LGD1069 on mammary carcinoma after tamoxifen failure. **1999**, 91, 2118		51
891	Peroxisome proliferator-activated receptor gamma activation in human breast cancer. *International Journal of Oncology*, **1999**, 15, 967-73	1	11
890	Pharmacological peroxisome proliferator-activated receptorgamma ligands: emerging clinical indications beyond diabetes. **1999**, 8, 1859-1872		17
889	Influence of J series prostaglandins on apoptosis and tumorigenesis of breast cancer cells. **1999**, 20, 1905-11		161
888	Constitutively active mitogen-activated protein kinase kinase 6 (MKK6) or salicylate induces spontaneous 3T3-L1 adipogenesis. **1999**, 274, 35630-8		90
887	Identification of ARA70 as a ligand-enhanced coactivator for the peroxisome proliferator-activated receptor gamma. **1999**, 274, 16147-52		102
886	Peroxisome proliferators enhance cyclooxygenase-2 expression in epithelial cells. **1999**, 274, 8328-34		220
885	The role of cyclooxygenase inhibition in the antineoplastic effects of nonsteroidal antiinflammatory drugs (NSAIDs). **1999**, 190, 445-50		135
884	Impairment of peroxisomal biogenesis in human colon carcinoma. **1999**, 20, 985-9		51
883	Differential expression of cyclooxygenase 2 in human colorectal cancer. **1999**, 45, 730-2		93
882	Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo. **1999**, 274, 9116-21		416
881	Use of a PPAR gamma-specific monoclonal antibody to demonstrate thiazolidinediones induce PPAR gamma receptor expression in vitro. **1999**, 18, 273-80		12
880	Newswatch. **1999**, 2, 77-81		

879	Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. **1999**, 96, 3951-6		414
878	Peroxisome proliferator-activated receptor beta regulates acyl-CoA synthetase 2 in reaggregated rat brain cell cultures. **1999**, 274, 35881-8		102
877	Thiazolidinediones: a new class of antidiabetic drugs. **1999**, 16, 179-92		350
876	Peroxisome proliferator-activated receptor gamma induces growth arrest and differentiation markers of human colon cancer cells. **1999**, 90, 75-80		213
875	Nonsteroidal anti-inflammatory drugs and the induction of apoptosis in colon cells: evidence for PHS-dependent and PHS-independent mechanisms. **1999**, 4, 373-81		11
874	PPARgamma, the ultimate thrifty gene. **1999**, 42, 1033-49		534
873	Cross-regulation of beta-catenin-LEF/TCF and retinoid signaling pathways. **1999**, 9, 1415-8		214
872	Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in human transitional bladder cancer and its role in inducing cell death. *Neoplasia*, **1999**, 1, 330-9	6.4	125
871	Peroxisome proliferator-activated receptors: nuclear control of metabolism. **1999**, 20, 649-88		2239
870	Orphan nuclear receptors: shifting endocrinology into reverse. **1999**, 284, 757-60		427
869	Orphan nuclear receptors: from gene to function. **1999**, 20, 689-725		564
868	Peroxisome proliferator-activated receptor-gamma: a versatile metabolic regulator. **1999**, 31, 342-51		72
867	PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. **1999**, 4, 611-7		1587
866	Loss-of-function mutations in PPAR gamma associated with human colon cancer. **1999**, 3, 799-804		438
865	Medical significance of peroxisome proliferator-activated receptors. **1999**, 354, 141-8		402
864	Cyclooxygenase-dependent signalling: molecular events and consequences. **1999**, 445, 1-5		33
863	Activation of PPARgamma inhibits cell growth and induces apoptosis in human gastric cancer cells. **1999**, 455, 135-9		192
862	Substitution of a conserved amino acid residue alters the ligand binding properties of peroxisome proliferator activated receptors. **1999**, 463, 205-10		7

861	PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. **1999**, 99, 335-45		956
860	An adipogenic cofactor bound by the differentiation domain of PPARgamma. **1999**, 18, 3676-87		95
859	Regulation of 12-lipoxygenase in rat intestinal epithelial cells during differentiation and apoptosis induced by sodium butyrate. **1999**, 368, 45-55		33
858	Advanced glycation end product-induced peroxisome proliferator-activated receptor gamma gene expression in the cultured mesangial cells. **1999**, 264, 441-8		51
857	PPARgamma inhibits the expression of c-MET in human gastric cancer cells through the suppression of Ets. **1999**, 265, 453-6		35
856	The peroxisome proliferator-activated receptor(PPARgamma) as a regulator of monocyte/macrophage function. **1999**, 66, 733-9		244
855	Regulation of macrophage gene expression by peroxisome-proliferator-activated receptor gamma: implications for cardiovascular disease. **1999**, 10, 485-90		45
854	Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. **2000**, 97, 13275-80		342
853	Antimutagenic and some other effects of conjugated linoleic acid. **2000**, 83, 459-465		155
852	Peroxisome-proliferator-activated receptor □mediates the effects of long-chain fatty acids on post-confluent cell proliferation. *Biochemical Journal*, **2000**, 350, 93	3.8	20
851	Peroxisome-proliferator-activated receptor □mediates the effects of long-chain fatty acids on post-confluent cell proliferation. *Biochemical Journal*, **2000**, 350, 93-98	3.8	50
850	Photoreceptor phagocytosis selectively activates PPARgamma expression in retinal pigment epithelial cells. **2000**, 60, 328-37		61
849	Peroxisome proliferator-activated receptors are expressed in human cultured mast cells: a possible role of these receptors in negative regulation of mast cell activation. **2000**, 30, 3363-70		63
848	Activators of peroxisome proliferator-activated receptor-alpha partially inhibit mouse skin tumor promotion. **2000**, 29, 134-42		65
847	Role of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) and its natural ligand 15-deoxy-Delta12, 14-prostaglandin J2 in the regulation of microglial functions. **2000**, 12, 2215-23		189
846	Peroxisome proliferator-activated receptors in tumorigenesis: targets of tumour promotion and treatment. **2000**, 78, 436-41		61
845	Troglitazone prevents fatty changes of the liver in obese diabetic rats. **2000**, 15, 1183-91		21
844	Peroxisome proliferator-activated receptors in the cardiovascular system. **2000**, 129, 823-34		272

843	Cyclooxygenase-2 and carcinogenesis. **2000**, 1470, M69-78		159
842	The role of peroxisome proliferator-activated receptor gamma in bladder cancer in relation to angiogenesis and progression. **2000**, 35, 269-75		20
841	Prostaglandins and fatty acids regulate transcriptional signaling via the peroxisome proliferator activated receptor nuclear receptors. **2000**, 62, 1-13		44
840	15-deoxy-Delta(12,14)PGJ(2) induces diverse biological responses via PPARgamma activation in cancer cells. **2000**, 62, 23-32		33
839	Peroxisome proliferator-activated receptors: insight into multiple cellular functions. **2000**, 448, 121-38		357
838	Regulation of TRAIL-induced apoptosis by transcription factors. **2000**, 201, 77-82		58
837	Peroxisome proliferator-activated receptors, coactivators, and downstream targets. **2000**, 32 Spring, 187-204		176
836	Modulation of metabolism through transcriptional control has created new treatment opportunities for type 2 diabetes. *Current Pharmaceutical Biotechnology*, **2000**, 1, 63-71	2.6	4
835	Transcriptional control of adipogenesis. **2000**, 20, 535-59		265
834	Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. **2000**, 97, 10990-5		362
833	15-LOX-1: a novel molecular target of nonsteroidal anti-inflammatory drug-induced apoptosis in colorectal cancer cells. **2000**, 92, 1136-42		121
832	Tumor selective G2/M cell cycle arrest and apoptosis of epithelial and hematological malignancies by BBL22, a benzazepine. **2000**, 97, 7494-9		66
831	Expression of peroxisome proliferator-activated receptor (PPAR)gamma in gastric cancer and inhibitory effects of PPARgamma agonists. **2000**, 83, 1394-400		192
830	Nuclear receptors in metabolic diseases. **2000**, 4, 377-396		4
829	Troglitazone improves psoriasis and normalizes models of proliferative skin disease: ligands for peroxisome proliferator-activated receptor-gamma inhibit keratinocyte proliferation. **2000**, 136, 609-16		159
828	PPARgamma ligand (thiazolidinedione) induces growth arrest and differentiation markers of human pancreatic cancer cells. *International Journal of Oncology*, **2000**, 17, 1157-64	1	24
827	Peroxisome proliferator-activated receptor gamma target gene encoding a novel angiopoietin-related protein associated with adipose differentiation. **2000**, 20, 5343-9		324
826	Peroxisome proliferator-activated receptor gamma ligands inhibit retinoblastoma phosphorylation and G1--> S transition in vascular smooth muscle cells. **2000**, 275, 22435-41		175

825	The nuclear receptor PPAR gamma and immunoregulation: PPAR gamma mediates inhibition of helper T cell responses. **2000**, 164, 1364-71	407
824	Regulation of lipid and lipoprotein metabolism by PPAR activators. **2000**, 38, 3-11	184
823	Over-representation of PPARgamma sequence variants in sporadic cases of glioblastoma multiforme: preliminary evidence for common low penetrance modifiers for brain tumour risk in the general population. **2000**, 37, 410-4	23
822	Pathophysiology and pharmacological treatment of insulin resistance. **2000**, 21, 585-618	222
821	Differential expression of peroxisome proliferator-activated receptors (PPARs) in the developing human fetal digestive tract. **2000**, 48, 603-11	67
820	PPAR-gamma is selectively upregulated in Caco-2 cells by butyrate. **2000**, 272, 380-5	71
819	Prostaglandins up-regulate vascular endothelial growth factor production through distinct pathways in differentiated U937 cells. **2000**, 273, 485-91	71
818	Inhibition of the terminal stages of adipocyte differentiation by cMyc. **2000**, 254, 91-8	26
817	Lack of cyclooxygenase-2 activity in HT-29 human colorectal carcinoma cells. **2000**, 256, 563-70	49
816	Presence and inducibility of peroxisomes in a human glioblastoma cell line. **2000**, 1474, 397-409	23
815	PPAR-gamma agonists: therapeutic role in diabetes, inflammation and cancer. **2000**, 21, 469-74	327
814	Activation of PPARgamma may mediate a portion of the anticancer activity of conjugated linoleic acid. **2000**, 55, 187-8	36
813	Peroxisome proliferator activated receptor-gamma (PPAR-gamma) mediates the action of gamma linolenic acid in breast cancer cells. **2000**, 62, 119-27	61
812	Chemoprevention of cancer. **2000**, 21, 525-30	375
811	Cancer chemoprevention through interruption of multistage carcinogenesis. The lessons learnt by comparing mouse skin carcinogenesis and human large bowel cancer. **2000**, 36, 314-29	103
810	Troglitazone and related compounds: therapeutic potential beyond diabetes. **2000**, 67, 2405-16	47
809	Pathophysiology and Pharmacological Treatment of Insulin Resistance. **2000**, 21, 585-618	111
808	PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. **2000**, 289, 1357-60	719

807	Mechanisms linking diet and colorectal cancer: the possible role of insulin resistance. **2000**, 37, 19-26	139
806	[PPARgamma and thiazolidinediones, something more than a treatment for diabetes]. **2000**, 115, 392-7	2
805	The genetic basis of colorectal cancer: insights into critical pathways of tumorigenesis. **2000**, 119, 854-65	323
804	Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells. **2000**, 119, 466-78	351
803	The PPARs: from orphan receptors to drug discovery. **2000**, 43, 527-50	1561
802	Inflammatory bowel disease: immunodiagnostics, immunotherapeutics, and ecotherapeutics. **2001**, 120, 622-35	272
801	The molecular basis for prevention of colorectal cancer. **2001**, 1, 47-54	8
800	Peroxisome proliferator-activated receptor gamma (PPARgamma) activation and its consequences in humans. **2001**, 120, 9-19	28
799	Troglitazone inhibits growth of MCF-7 breast carcinoma cells by targeting G1 cell cycle regulators. **2001**, 286, 916-22	111
798	Expression of peroxisome proliferator-activated receptor gamma in renal cell carcinoma and growth inhibition by its agonists. **2001**, 287, 727-32	82
797	Effect of PPAR activators on cytokine-stimulated cyclooxygenase-2 expression in human colorectal carcinoma cells. **2001**, 267, 73-80	36
796	Effects of peroxisome proliferator-activated receptor-gamma (PPAR-gamma) on the expression of inflammatory cytokines and apoptosis induction in rheumatoid synovial fibroblasts and monocytes. **2001**, 17, 215-21	64
795	Role of peroxisome proliferator-activated receptor gamma and its ligands in non-neoplastic and neoplastic human urothelial cells. **2001**, 159, 591-7	73
794	Current prospects for controlling cancer growth with non-cytotoxic agents--nutrients, phytochemicals, herbal extracts, and available drugs. **2001**, 56, 137-54	27
793	Peroxisome proliferator-activated receptor- gamma expression in human malignant and normal brain, breast and prostate-derived cells. **2001**, 64, 241-5	48
792	Peroxisome proliferator-activated receptor (PPAR) gamma agonists for diabetes. **2001**, 56, 181-212	31
791	PPARgamma and inflammatory bowel disease: a new therapeutic target for ulcerative colitis and Crohn's disease. **2001**, 7, 329-31	62
790	Prospects for prevention and treatment of cancer with selective PPARgamma modulators (SPARMs). **2001**, 7, 395-400	126

789	Suppression of inducible cyclooxygenase and nitric oxide synthase through activation of peroxisome proliferator-activated receptor-gamma by flavonoids in mouse macrophages. **2001**, 496, 12-8		170
788	Other novel agents: Rationale and current status as chemopreventive agents. **2001**, 57, 86-9		13
787	Production of matrix metalloproteinase-9 in CaCO-2 cells in response to inflammatory stimuli. **2001** , 21, 93-8		53
786	Fluorine-substituted ligands for the peroxisome proliferator-activated receptor gamma (PPARgamma): potential imaging agents for metastatic tumors. **2001**, 12, 439-50		7
785	Cyclooxygenase-independent actions of cyclooxygenase inhibitors. **2001**, 15, 2057-72		642
784	Activation of peroxisome proliferator-activated receptor gamma inhibits the growth of human pancreatic cancer. **2001**, 69, 258-65		14
783	Peroxisome proliferator-activated receptors: roles in tumorigenesis and chemoprevention in human cancer. *Current Opinion in Oncology*, **2001**, 13, 78-83	4.2	32
782	Nonsteroidal antiinflammatory drugs, cyclooxygenase-2, and colorectal cancer prevention. **2001**, 17, 65-71		5
781	Magnitude of peroxisome proliferator-activated receptor-gamma activation is associated with important and seemingly opposite biological responses in breast cancer cells. **2001**, 49, 413-20		55
780	Peroxisomal alterations in aging and age-related disease. **2001**, 7, 1-28		2
779	Nonhypoglycemic effects of thiazolidinediones. **2001**, 134, 61-71		304
778	The pleiotropic functions of peroxisome proliferator-activated receptor gamma. **2001**, 79, 30-47		175
777	Opposite association of two PPARG variants with cancer: overrepresentation of H449H in endometrial carcinoma cases and underrepresentation of P12A in renal cell carcinoma cases. **2001**, 109, 146-51		36
776	Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease. **2001**, 60, 14-30		220
775	Deletion at 3p25.3-p23 is frequently encountered in endocrine pancreatic tumours and is associated with metastatic progression. **2001**, 194, 451-8		72
774	Oncostatic activity of a thiazolidinedione derivative on human androgen-dependent prostate cancer cells. **2001**, 92, 733-7		20
773	PPARgamma agonists inhibit cell growth and suppress the expression of cyclin D1 and EGF-like growth factors in ras-transformed rat intestinal epithelial cells. **2001**, 94, 335-42		39
772	Ligands for peroxisome proliferator-activated receptor gamma inhibit growth of pancreatic cancers both in vitro and in vivo. **2001**, 94, 370-6		56

771	Involvement of p21(WAF1/Cip1), p27(Kip1), and p18(INK4c) in troglitazone-induced cell-cycle arrest in human hepatoma cell lines. **2001**, 33, 1087-97	123
770	COX-2 and cancer: a new approach to an old problem. **2001**, 134, 1137-50	89
769	Troglitazone, a ligand for peroxisome proliferator-activated receptor gamma, inhibits chemically-induced aberrant crypt foci in rats. **2001**, 92, 396-403	46
768	Prostaglandin-J2 induces synthesis of interleukin-8 by endothelial cells in a PPAR-gamma-independent manner. **2001**, 66, 165-77	51
767	Binding of prostaglandins to human PPARgamma: tool assessment and new natural ligands. **2001**, 417, 77-89	44
766	Tumor suppressor and anti-inflammatory actions of PPARgamma agonists are mediated via upregulation of PTEN. **2001**, 11, 764-8	306
765	Peroxisome proliferator-activated receptor gamma-mediated transcriptional up-regulation of the hepatocyte growth factor gene promoter via a novel composite cis-acting element. **2001**, 276, 25049-56	39
764	Target genes of peroxisome proliferator-activated receptor gamma in colorectal cancer cells. **2001**, 276, 29681-7	153
763	Pioglitazone inhibits growth of carcinoid cells and promotes TRAIL-induced apoptosis by induction of p21waf1/cip1. **2001**, 64, 75-80	55
762	Troglitazone treatment increases plasma vascular endothelial growth factor in diabetic patients and its mRNA in 3T3-L1 adipocytes. **2001**, 50, 1166-70	84
761	PPAR-□ligands inhibit growth of human esophageal adenocarcinoma cells through induction of apoptosis, cell cycle arrest and reduction of ornithine decarboxylase activity. **2001**, 19, 465	2
760	Peroxisome proliferator-activated receptor gamma ligand-induced growth inhibition of human hepatocellular carcinoma. **2001**, 84, 1640-7	70
759	Activation of the PPAR pathway induces apoptosis and COX-2 inhibition in HT-29 human colon cancer cells. **2001**, 22, 1379-83	160
758	15-lipoxygenase-1 metabolites down-regulate peroxisome proliferator-activated receptor gamma via the MAPK signaling pathway. **2001**, 276, 34545-52	76
757	Genetic disruption of PPARdelta decreases the tumorigenicity of human colon cancer cells. **2001**, 98, 2598-603	225
756	Peroxisome proliferator-activated receptor gamma and chicken ovalbumin upstream promoter transcription factor II negatively regulate the phosphoenolpyruvate carboxykinase promoter via a common element. **2001**, 276, 30561-9	30
755	Tetradecylthioacetic acid inhibits growth of rat glioma cells ex vivo and in vivo via PPAR-dependent and PPAR-independent pathways. **2001**, 22, 1747-55	56
754	PPARgamma : a nuclear regulator of metabolism, differentiation, and cell growth. **2001**, 276, 37731-4	903

753	Peroxisome proliferator-activated receptor-gamma: from adipogenesis to carcinogenesis. **2001**, 27, 1-9	197
752	Inhibition of cellular proliferation through IkappaB kinase-independent and peroxisome proliferator-activated receptor gamma-dependent repression of cyclin D1. **2001**, 21, 3057-70	149
751	Heat shock proteins: new keys to the development of cytoprotective therapies. **2001**, 5, 267-87	52
750	Albumin regulates induction of peroxisome proliferator-activated receptor-gamma (PPARgamma) by 15-deoxy-delta(12-14)-prostaglandin J(2) in vitro and may be an important regulator of PPARgamma function in vivo. **2001**, 142, 551-6	14
749	Loss of the peroxisome proliferation-activated receptor gamma (PPARgamma) does not affect mammary development and propensity for tumor formation but leads to reduced fertility. **2002**, 277, 17830-5	135
748	Decreased peroxisome proliferator-activated receptor gamma gene expression is correlated with poor prognosis in patients with esophageal cancer. **2002**, 32, 238-43	56
747	Opposing effects of 15-lipoxygenase-1 and -2 metabolites on MAPK signaling in prostate. Alteration in peroxisome proliferator-activated receptor gamma. **2002**, 277, 40549-56	116
746	APC-dependent suppression of colon carcinogenesis by PPARgamma. **2002**, 99, 13771-6	232
745	Glitazones: clinical effects and molecular mechanisms. **2002**, 34, 217-224	169
744	Peroxisome proliferator-activated receptor-gamma agonist 15-deoxy-Delta(12,14)-prostaglandin J(2) ameliorates experimental autoimmune encephalomyelitis. **2002**, 168, 2508-15	263
743	Diclofenac antagonizes peroxisome proliferator-activated receptor-gamma signaling. **2002**, 61, 7-12	71
742	Steroid Hormones and Cell Cycle Regulation. **2002**,	0
741	Chemoprevention of breast cancer by targeting cyclooxygenase-2 and peroxisome proliferator-activated receptor- (Review). **2002**, 20, 1109	3
740	Frequent polymorphism of peroxisome proliferator activated receptor gene in colorectal cancer containing wild-type K-ras gene. **2002**, 9, 485	
739	Expression of peroxisome proliferator-activated receptor and the growth inhibitory effect of its synthetic ligands in human salivary gland cancer cell lines. **2002**, 20, 599	
738	Thiazolidinedione, a peroxisome proliferator-activated receptor- ligand, modulates the E-cadherin/ catenin system in a human pancreatic cancer cell line, BxPC-3. **2002**, 21, 37	3
737	Novel insulin sensitizers: pharmacogenomic aspects. **2002**, 3, 99-116	31
736	Ligands for the peroxisomal proliferator-activated receptor gamma and the retinoid X receptor inhibit aromatase cytochrome P450 (CYP19) expression mediated by promoter II in human breast adipose. **2002**, 143, 2863-71	44

735	Inhibitory effects of peroxisome poliferator-activated receptor gamma on thyroid carcinoma cell growth. **2002**, 87, 4728-35		118
734	Characteristics of the peroxisome proliferator activated receptor gamma (PPARgamma) ligand induced apoptosis in colon cancer cells. **2002**, 50, 658-64		167
733	Molecular targets in breast cancer: current status and future directions. **2002**, 9, 249-66		10
732	Controversy: PPARgamma as a target for treatment of colorectal cancer. *American Journal of Physiology - Renal Physiology*, **2002**, 283, G266-9	5.1	47
731	A ligand for peroxisome proliferator activated receptor gamma inhibits cell growth and induces apoptosis in human liver cancer cells. **2002**, 50, 563-7		75
730	Becoming fat. *Genes and Development*, **2002**, 16, 1-5	12.6	51
729	Putative activation of the peroxisome proliferator-activated receptor gamma impairs androgen and enhances progesterone biosynthesis in primary cultures of porcine theca cells. **2002**, 66, 190-8		69
728	15-Deoxy-delta12,14-prostaglandin J2-induced apoptosis does not require PPARgamma in breast cancer cells. **2002**, 43, 1818-28		82
727	Ligands of peroxisome proliferator-activated receptor-gamma induce apoptosis in AR42J cells. **2002**, 24, 130-8		39
726	Peroxisome proliferator-activated receptor gamma augments tumor necrosis factor family-induced apoptosis in hepatocellular carcinoma. **2002**, 13, 59-65		11
725	A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer. **2002**, 8, 395-9		123
724	Lack of association of the codon 12 polymorphism of the peroxisome proliferator-activated receptor gamma gene with breast cancer and body mass. **2002**, 12, 597-603		38
723	Role of peroxisome proliferator-activated receptor-gamma in hematologic malignancies. **2002**, 9, 294-302		29
722	Growth inhibition and differentiation of pancreatic cancer cell lines by PPAR gamma ligand troglitazone. **2002**, 24, 1-7		57
721	The triterpenoid CDDO induces apoptosis in refractory CLL B cells. **2002**, 100, 2965-72		146
720	An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis. **2002**, 277, 22320-9		239
719	Arachidonic and linoleic acid metabolism in mouse intestinal tissue: evidence for novel lipoxygenase activity. **2002**, 398, 51-60		13
718	National Cancer Institute workshop on chemopreventive properties of nonsteroidal anti-inflammatory drugs: role of COX-dependent and -independent mechanisms. *Neoplasia*, **2002**, 4, 91-7	6.4	43

717	Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux. **2002**, 22, 2607-19		333
716	Thrombomodulin expression by THP-1 but not by vascular endothelial cells is upregulated by pioglitazone. **2002**, 108, 227-34		13
715	Expression of peroxisome proliferator-activated receptors in human testicular cancer and growth inhibition by its agonists. **2002**, 60, 542-7		55
714	Butyrate reduces colonic paracellular permeability by enhancing PPARgamma activation. **2002**, 293, 827-31		125
713	Peroxisome proliferator-activated receptor ligands negatively regulate the expression of the high-affinity IgE receptor Fc epsilon RI in human basophilic KU812 cells. **2002**, 297, 193-201		21
712	Docosahexaenoic acid suppresses the activity of peroxisome proliferator-activated receptors in a colon tumor cell line. **2002**, 298, 667-74		39
711	Apoptosis induced by activation of peroxisome-proliferator activated receptor-gamma is associated with Bcl-2 and NF-kappaB in human colon cancer. **2002**, 70, 2631-46		109
710	Decreased perioxisome proliferator-activated receptor gamma gene expression was correlated with poor prognosis in patients with lung cancer. **2002**, 36, 71-6		62
709	Antineoplastic properties of arachidonic acid and its metabolites. **2002**, 66, 5-12		14
708	Peroxisome proliferator-activated receptor gamma (PPARgamma) and its ligands: a review. **2002**, 22, 1-23		168
707	Conjugated linoleic acid decreases production of pro-inflammatory products in macrophages: evidence for a PPAR gamma-dependent mechanism. **2002**, 1581, 89-99		243
706	Troglitazone ameliorates lipotoxicity in the beta cell line INS-1 expressing PPAR gamma. **2002**, 56, 83-92		17
705	The antiproliferative effects of biologically active isomers of conjugated linoleic acid on human colorectal and prostatic cancer cells. **2002**, 177, 163-72		133
704	Troglitazone activates p21Cip/WAF1 through the ERK pathway in HCT15 human colorectal cancer cells. **2002**, 179, 185-95		29
703	The mechanisms of action of PPARs. **2002**, 53, 409-35		1974
702	Redifferentiation Therapy in Thyroid Cancer. **2002**, 2, 83		
701	Nuclear receptors. I. PPAR gamma in the gastrointestinal tract: gain or pain?. *American Journal of Physiology - Renal Physiology*, **2002**, 282, G581-5	5.1	45
700	Enhanced hepatocarcinogenicity due to agonists of peroxisome proliferator-activated receptors in senescent rats: role of peroxisome proliferation, cell proliferation, and apoptosis. **2002**, 2, 1491-500		12

699 PPAR. **2002**, 141-158

698 Growth inhibition of esophageal squamous carcinoma cells by peroxisome proliferator-activated receptor-gamma ligands. **2002**, 140, 17-26 29

697 Leptin and high glucose stimulate cell proliferation in MCF-7 human breast cancer cells: reciprocal involvement of PKC-alpha and PPAR expression. **2002**, 1592, 107-16 152

696 Expression of peroxisome proliferator-activated receptors alpha and gamma in differentiating human colon carcinoma Caco-2 cells. **2002**, 94, 15-27 19

695 The pathophysiologic basis of efficacy and clinical experience with the new oral antidiabetic agents. **2002**, 16, 123-32 41

694 Anti-tumor mechanisms of valproate: a novel role for an old drug. **2002**, 22, 492-511 216

693 Pivotal role of G-protein□oupled adenosine A2a receptors in protection of the liver against inflammation and ischemia-reperfusion injury. **2002**, 36, 1009-1011 1

692 Hepatic stellate cells as a target for TZD: Can we treat liver fibrosis and type II diabetes at the same time?. **2002**, 36, 1011-1013 2

691 Troglitazione affects survival of human osteosarcoma cells. **2002**, 98, 344-51 27

690 PPARgamma-mediated antineoplastic effect of NSAID sulindac on human oral squamous carcinoma cells. **2002**, 98, 817-23 43

689 Peroxisome proliferator-activated receptor gamma ligand troglitazone induces cell cycle arrest and apoptosis of hepatocellular carcinoma cell lines. **2002**, 95, 2243-51 62

688 The effect of 15-lipoxygenase-1 expression on cancer cells. **2002**, 3, 207-14 56

687 Induction of apoptosis in human and rat glioma by agonists of the nuclear receptor PPARgamma. **2002**, 81, 1052-60 108

686 Agonists of peroxisome proliferator-activated receptor gamma inhibit cell growth in malignant melanoma. **2002**, 119, 576-82 64

685 Effect of PPARgamma ligands on the viability of gastric epithelial cells. **2002**, 16 Suppl 2, 67-73 16

684 Review article: COX-2, prostanoids and colon cancer. **2002**, 16 Suppl 2, 102-6 26

683 PPARgamma and the thiazolidinediones: molecular basis for a treatment of □yndrome X□. **2002**, 4, 239-48 17

682 Peroxisome proliferator-activated receptor gamma activation induces cell cycle arrest via the p53-independent pathway in human anaplastic thyroid cancer cells. **2002**, 93, 1358-65 45

681	Troglitazone induces G1 arrest by p27(Kip1) induction that is mediated by inhibition of proteasome in human gastric cancer cells. **2002**, 93, 774-82		21
680	Ligand activation of peroxisome proliferator-activated receptor gamma induces apoptosis of leukemia cells by down-regulating the c-myc gene expression via blockade of the Tcf-4 activity. **2002**, 9, 513-26		53
679	Peroxisome proliferator-activated receptor-gamma agonists inhibit experimental allergic encephalomyelitis by blocking IL-12 production, IL-12 signaling and Th1 differentiation. **2002**, 3, 59-70		192
678	Activation of peroxisome proliferator-activated receptor-gamma stimulates the growth arrest and DNA-damage inducible 153 gene in non-small cell lung carcinoma cells. **2002**, 21, 2171-80		96
677	Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. *Nature Medicine*, **2002**, 8, 1281-7	50.5	202
676	Inhibition of human chondrosarcoma cell growth via apoptosis by peroxisome proliferator-activated receptor-gamma. **2002**, 86, 1303-9		27
675	15-PGJ2, but not thiazolidinediones, inhibits cell growth, induces apoptosis, and causes downregulation of Stat3 in human oral SCCa cells. **2002**, 87, 1396-403		49
674	Decreased synthesis of matrix metalloproteinase-7 and adhesion to the extracellular matrix proteins of human colon cancer cells treated with troglitazone. **2002**, 32, 343-50		20
673	Peroxisome proliferator-activated receptor gamma (PPargamma) as a novel target for prostate cancer. **2002**, 20, 195-200		21
672	Novel therapeutic approach: ligands for PPARgamma and retinoid receptors induce apoptosis in bcl-2-positive human breast cancer cells. **2002**, 74, 155-65		72
671	Peroxisome proliferator-activated receptor gamma ligand inhibits cell growth and invasion of human pancreatic cancer cells. **2002**, 32, 7-22		41
670	Induction and repression of peroxisome proliferator-activated receptor alpha transcription by coregulator ARA70. **2003**, 21, 139-46		9
669	The antiproliferative effects of PPARgamma ligands in normal human mammary epithelial cells. **2003**, 78, 179-92		26
668	PPARgamma ligands and ATRA inhibit the invasion of human breast cancer cells in vitro. **2003**, 79, 63-74		126
667	Novel agents for the prevention of breast cancer: targeting transcription factors and signal transduction pathways. **2003**, 8, 45-73		51
666	Ligands for PPARgamma and RAR cause induction of growth inhibition and apoptosis in human glioblastomas. **2003**, 65, 107-18		49
665	Hydrogen peroxide overproduction in megamitochondria of troglitazone-treated human hepatocytes. **2003**, 37, 136-47		58
664	Troglitazone induces p27Kip1-associated cell-cycle arrest through down-regulating Skp2 in human hepatoma cells. **2003**, 37, 1086-96		51

663	Thiazolidinediones inhibit cell growth of human oral squamous cell carcinoma in vitro independent of peroxisome proliferator-activated receptor gamma. **2003**, 39, 855-61	15
662	DR1-like element in human topoisomerase IIalpha gene involved in enhancement of etoposide-induced apoptosis by PPARgamma ligand. **2003**, 31, 300-8	9
661	The potential contributions of chronic inflammation to lung carcinogenesis. **2003**, 5, 46-62	152
660	Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands as bifunctional regulators of cell proliferation. **2003**, 66, 1381-91	106
659	Differentiating agents and the treatment of prostate cancer: Vitamin D3 and peroxisome proliferator-activated receptor gamma ligands. **2003**, 30, 698-708	12
658	The development of differentiation agents for the treatment of prostate cancer. **2003**, 30, 689-97	4
657	Hepatocellular carcinoma: is there a potential for chemoprevention using cyclooxygenase-2 inhibitors?. **2003**, 98, 661-7	35
656	Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors. **2003**, 98, 2251-6	121
655	Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists. **2003**, 104, 597-602	86
654	15-hydroxy-eicosatetraenoic acid arrests growth of colorectal cancer cells via a peroxisome proliferator-activated receptor gamma-dependent pathway. **2003**, 107, 837-43	64
653	Phosphorylation of PPARgamma via active ERK1/2 leads to its physical association with p65 and inhibition of NF-kappabeta. **2003**, 90, 732-44	123
652	15-deoxy-delta12,14 prostaglandin J2 synergizes with phorbol ester to induce proliferation in Swiss 3T3 cells independently of peroxisome proliferator-activated receptor gamma and PGD2 receptors. **2003**, 195, 421-7	3
651	Primary culture model of peroxisome proliferator-activated receptor gamma activity in prostate cancer cells. **2003**, 196, 131-43	40
650	Inhibition of glial cell proinflammatory activities by peroxisome proliferator-activated receptor gamma agonist confers partial protection during antimyelin oligodendrocyte glycoprotein demyelination in vitro. **2003**, 71, 246-55	26
649	Effects of peroxisome proliferator-activated receptor gamma ligands ciglitazone and 15-deoxy-delta 12,14-prostaglandin J2 on rat cultured cerebellar granule neuronal viability. **2003**, 72, 747-55	26
648	Role of nuclear receptors in the regulation of gene expression by dietary fatty acids (review). **2003**, 14, 554-67	120
647	Advances in understanding the regulation of apoptosis and mitosis by peroxisome-proliferator activated receptors in pre-clinical models: relevance for human health and disease. **2003**, 2, 3	54
646	Up-regulation of TFF expression by PPARgamma ligands in gastric epithelial cells. **2003**, 18 Suppl 1, 119-25	8

645	Peroxisome proliferator-activated receptors in cutaneous biology. **2003**, 149, 229-36		98
644	PPAR gamma ligand-induced apoptosis through a p53-dependent mechanism in human gastric cancer cells. **2003**, 94, 338-43		57
643	15-deoxy-delta-12-14-PGJ2 regulates apoptosis induction and nuclear factor-kappaB activation via a peroxisome proliferator-activated receptor-gamma-independent mechanism in hepatocellular carcinoma. **2003**, 83, 1529-39		36
642	Expression of peroxisome proliferator-activated receptor gamma in salivary duct carcinoma: immunohistochemical analysis of 15 cases. **2003**, 16, 1218-23		24
641	Genetic deficiency in Pparg does not alter development of experimental prostate cancer. *Nature Medicine*, **2003**, 9, 1265-6	50.5	25
640	Peroxisome proliferator-activated receptor gamma ligands suppress colon carcinogenesis induced by azoxymethane in mice. **2003**, 124, 361-7		161
639	PPARgamma ligands: taking Ppart in chemoprevention. **2003**, 124, 564-7		23
638	Selective activation of PPARgamma inhibits pancreatic cancer invasion and decreases expression of tissue plasminogen activator. **2003**, 134, 206-12		20
637	Colonic polyps of acromegalic patients are not associated with mutations of the peroxisome proliferator activated receptor gamma gene. **2003**, 26, 1054-8		3
636	Bezafibrate induces a mitochondrial derangement in human cell lines: a PPAR-independent mechanism for a peroxisome proliferator. **2003**, 16, 1440-7		34
635	Roles of peroxisome proliferator-activated receptors delta and gamma in myoblast transdifferentiation. **2003**, 288, 168-76		50
634	Thiazolidinediones inhibit growth of gastrointestinal, biliary, and pancreatic adenocarcinoma cells through activation of the peroxisome proliferator-activated receptor gamma/retinoid X receptor alpha pathway. **2003**, 289, 143-51		28
633	Evaluation of eicosanoids and NSAIDs as PPARgamma ligands in colorectal carcinoma cells. **2003**, 68, 323-30		22
632	Growth inhibition through activation of peroxisome proliferator-activated receptor gamma in human oesophageal squamous cell carcinoma. **2003**, 39, 2239-46		18
631	Animal Cell Technology: Basic & Applied Aspects. **2003**,		1
630	Modified fatty acids and their possible therapeutic targets in malignant diseases. **2003**, 7, 663-77		16
629	Activation and binding of peroxisome proliferator-activated receptor gamma by synthetic cannabinoid ajulemic acid. **2003**, 63, 983-92		108
628	Troglitazone, a peroxisome proliferator-activated receptor gamma (PPAR gamma) ligand, selectively induces the early growth response-1 gene independently of PPAR gamma. A novel mechanism for its anti-tumorigenic activity. **2003**, 278, 5845-53		154

627	Effect of topical PPARbeta/delta and PPARgamma agonists on plaque psoriasis. A pilot study. **2003**, 206, 252-6		50
626	Peroxisome proliferator-activated receptor-gamma-deficient heterozygous mice develop an exacerbated neural antigen-induced Th1 response and experimental allergic encephalomyelitis. **2003**, 171, 5743-50		93
625	Therapeutic potential of thiazolidinediones as anticancer agents. **2003**, 12, 1925-37		68
624	Tumor Suppressor Genes. **2003**,		
623	Aminosalicylates and colorectal cancer in IBD: a not-so bitter pill to swallow. **2003**, 98, 1682-7		40
622	Cyclooxygenase-independent induction of apoptosis by sulindac sulfone is mediated by polyamines in colon cancer. **2003**, 278, 47762-75		111
621	Peroxisome proliferator-activated receptor gamma-mediated differentiation: a mutation in colon cancer cells reveals divergent and cell type-specific mechanisms. **2003**, 278, 22669-77		44
620	Targeted elimination of peroxisome proliferator-activated receptor gamma in beta cells leads to abnormalities in islet mass without compromising glucose homeostasis. **2003**, 23, 7222-9		132
619	Cyclin D1 repression of peroxisome proliferator-activated receptor gamma expression and transactivation. **2003**, 23, 6159-73		184
618	Activation of PPAR gamma in colon tumor cell lines by oxidized metabolites of linoleic acid, endogenous ligands for PPAR gamma. **2003**, 24, 1717-22		54
617	Human invasive trophoblasts transformed with simian virus 40 provide a new tool to study the role of PPARgamma in cell invasion process. **2003**, 24, 1325-36		57
616	Thiazolidinediones -- some recent developments. **2003**, 12, 1179-87		52
615	The effect of peroxisome proliferator-activated receptor-□ligand on urological cancer cells. **2003**, 12, 861		1
614	Peroxisome proliferator-activated receptor gamma and transforming growth factor-beta pathways inhibit intestinal epithelial cell growth by regulating levels of TSC-22. **2003**, 278, 7431-8		62
613	Changes in the expression of the peroxisome proliferator-activated receptor gamma gene in the colonic polyps and colonic mucosa of acromegalic patients. **2003**, 88, 3938-42		15
612	Targets in apoptosis signaling: promise of selective anticancer therapy. **2003**, 223, 465-83		7
611	Germ cell tumors: review of selected studies from 2002. *Current Opinion in Oncology*, **2003**, 15, 234-8	4.2	7
610	Polyamines as modifiers of genetic risk factors in human intestinal cancers. **2003**, 31, 388-92		26

609	Mitochondrial Function in Cell Growth and Death. **2004**, 77-119		
608	Role of Peroxisome Proliferator-Activated Receptors in Inflammation Control. **2004**, 2004, 156-166		72
607	Peroxisome proliferator-activated receptor-gamma calls for activation in moderation: lessons from genetics and pharmacology. **2004**, 25, 899-918		234
606	Peroxisome proliferator-activated receptor gamma-dependent activation of p21 in Panc-28 pancreatic cancer cells involves Sp1 and Sp4 proteins. **2004**, 145, 5774-85		69
605	Signal transduction mediated by cyclin D1: from mitogens to cell proliferation: a molecular target with therapeutic potential. *Cancer Treatment and Research*, **2004**, 119, 217-37	3.5	66
604	Growth hormone inhibits apoptosis in human colonic cancer cell lines: antagonistic effects of peroxisome proliferator activated receptor-gamma ligands. **2004**, 145, 3353-62		24
603	15-deoxy-Delta-12,14-prostaglandin J2 induces programmed cell death of breast cancer cells by a pleiotropic mechanism. **2005**, 26, 81-92		56
602	Effect of peroxisome proliferator activated receptor gamma ligands on growth and gene expression profiles of gastric cancer cells. **2004**, 53, 331-8		56
601	The synthetic ligand of peroxisome proliferator-activated receptor-gamma ciglitazone affects human glioblastoma cell lines. **2004**, 309, 1239-47		54
600	Promotion of colon tumors in C57BL/6J-APC(min)/+ mice by thiazolidinedione PPARgamma agonists and a structurally unrelated PPARgamma agonist. **2004**, 32, 58-63		33
599	Cyclin D1 genetic heterozygosity regulates colonic epithelial cell differentiation and tumor number in ApcMin mice. **2004**, 24, 7598-611		137
598	Peroxisome proliferator-activated receptor gamma activation can regulate beta-catenin levels via a proteasome-mediated and adenomatous polyposis coli-independent pathway. **2004**, 279, 35583-94		106
597	Antiangiogenic therapy with pioglitazone, rofecoxib, and trofosfamide in a patient with endemic kaposi sarcoma. **2004**, 140, 1504-7		30
596	The PPAR{gamma} Pro12Ala polymorphism and risk for incident sporadic colorectal adenomas. **2005**, 26, 579-85		38
595	PPAR gamma signaling exacerbates mammary gland tumor development. *Genes and Development*, **2004**, 18, 528-40	12.6	143
594	Haploid inactivation of the amplified-in-breast cancer 3 coactivator reduces the inhibitory effect of peroxisome proliferator-activated receptor gamma and retinoid X receptor on cell proliferation and accelerates polyoma middle-T antigen-induced mammary tumorigenesis in mice. **2004**, 64, 7169-77		24
593	Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPARgamma independent mechanisms. **2004**, 53, 1688-97		66
592	Expression of NAG-1, a transforming growth factor-beta superfamily member, by troglitazone requires the early growth response gene EGR-1. **2004**, 279, 6883-92		107

591	Antitumor effects of peroxisome proliferator activate receptor ligands on anaplastic thyroid carcinoma. **2004**, 24, 89		1
590	The PPAR ligands PGJ2 and rosiglitazone show a differential ability to inhibit proliferation and to induce apoptosis and differentiation of human glioblastoma cell lines. **2004**, 25, 493		3
589	Thiazolidinedione, a peroxisome proliferator-activated receptor- ligand, inhibits growth and metastasis of HT-29 human colon cancer cells through differentiation-promoting effects. **2004**, 25, 631		4
588	PPARgamma signaling: one size fits all?. **2004**, 3, 1352-4		5
587	Answer. **2004**, 53, 338-338		1
586	Glitazones differentially regulate primary astrocyte and glioma cell survival. Involvement of reactive oxygen species and peroxisome proliferator-activated receptor-gamma. **2004**, 279, 8976-85		94
585	Transactivation of the PPAR-responsive enhancer module in chemopreventive glutathione S-transferase gene by the peroxisome proliferator-activated receptor-gamma and retinoid X receptor heterodimer. **2004**, 64, 3701-13		116
584	Underexpression of peroxisome proliferator-activated receptor (PPAR)gamma in PAX8/PPARgamma-negative thyroid tumours. **2004**, 91, 732-8		57
583	Lack of efficacy of troglitazone at clinically achievable concentrations, with or without 9-cis retinoic acid or cytotoxic agents, for hepatocellular carcinoma cell lines. **2004**, 91, 1561-5		5
582	Molecular Targeting and Signal Transduction. **2004**,		
581	Pomegranate seed oil rich in conjugated linolenic acid suppresses chemically induced colon carcinogenesis in rats. **2004**, 95, 481-6		201
580	Peroxisome proliferator-activated receptor gamma-dependent and -independent growth inhibition of gastrointestinal tumour cells. **2004**, 9, 1113-23		30
579	Troglitazone inhibits cyclin D1 expression and cell cycling independently of PPARgamma in normal mouse skin keratinocytes. **2004**, 123, 1110-9		30
578	PPARs and the complex journey to obesity. *Nature Medicine*, **2004**, 10, 355-61	50.5	1231
577	Peroxisome-proliferator-activated receptors and cancers: complex stories. **2004**, 4, 61-70		484
576	Peroxisome proliferator-activated receptor-gamma activation inhibits tumor progression in non-small-cell lung cancer. **2004**, 23, 100-8		177
575	The PAX8/PPARgamma fusion oncoprotein transforms immortalized human thyrocytes through a mechanism probably involving wild-type PPARgamma inhibition. **2004**, 23, 3634-41		80
574	Signaling pathways involved in induction of GADD45 gene expression and apoptosis by troglitazone in human MCF-7 breast carcinoma cells. **2004**, 23, 4614-23		72

573	Clinical implication of expression of cyclooxygenase-2 and peroxisome proliferator activated-receptor gamma in epithelial ovarian tumours. **2004**, 91, 633-8	38
572	Simultaneous, bidirectional inhibitory crosstalk between PPAR and STAT5b. **2004**, 199, 275-84	43
571	Dose-dependent transitions in mechanisms of toxicity: case studies. **2004**, 201, 226-94	141
570	Thiazolidinediones increase arachidonic acid release and subsequent prostanoid production in a peroxisome proliferator-activated receptor gamma-independent manner. **2004**, 73, 191-213	15
569	Inhibition of HER-kinase activation prevents ERK-mediated degradation of PPARgamma. **2004**, 5, 565-74	29
568	High prevalence of hyperplastic colonic polyps in acromegalic subjects. **2004**, 49, 662-6	12
567	Inhibition of cell invasion and morphological change by troglitazone in human pancreatic cancer cells. **2004**, 39, 461-8	31
566	Induction of differentiation and peroxisome proliferator-activated receptor gamma expression in colon cancer cell lines by troglitazone. **2004**, 130, 73-9	55
565	Crosstalk of oncogenic and prostanoid signaling pathways. **2004**, 130, 429-44	38
564	PPAR-gamma in Cushing's disease. **2004**, 7, 265-9	20
563	Rosiglitazone inhibits proliferation, motility, and matrix metalloproteinase production in keratinocytes. **2004**, 122, 130-9	46
562	Growth arrest by troglitazone is mediated by p27Kip1 accumulation, which results from dual inhibition of proteasome activity and Skp2 expression in human hepatocellular carcinoma cells. **2004**, 108, 41-6	51
561	Approaches to understanding the importance and clinical implications of peroxisome proliferator-activated receptor gamma (PPARgamma) signaling in prostate cancer. **2004**, 91, 513-27	27
560	Peroxisome proliferator-activated receptor gamma ligands induce growth inhibition and apoptosis of human B lymphocytic leukemia. **2004**, 28, 387-97	37
559	Novel medical approaches for the treatment of Cushing's disease. **2004**, 27, 591-5	7
558	Pleiotropic effects of thiazolidinediones: taking a look beyond antidiabetic activity. **2004**, 27, 982-91	110
557	Redifferentiation therapy for thyroid cancer. **2004**, 84, 921-43	22
556	Regulated production of a peroxisome proliferator-activated receptor-gamma ligand during an early phase of adipocyte differentiation in 3T3-L1 adipocytes. **2004**, 279, 36093-102	143

555	Capsaicin, a spicy component of hot pepper, induces apoptosis by activation of the peroxisome proliferator-activated receptor gamma in HT-29 human colon cancer cells. **2004**, 7, 267-73		90
554	1,1-Bis(3Pindolyl)-1-(p-substitutedphenyl)methanes induce peroxisome proliferator-activated receptor gamma-mediated growth inhibition, transactivation, and differentiation markers in colon cancer cells. **2004**, 64, 5994-6001		64
553	Role of PPARgamma and EGFR signalling in the urothelial terminal differentiation programme. *Journal of Cell Science*, **2004**, 117, 2029-36	5.3	138
552	Human multiple myeloma cells express peroxisome proliferator-activated receptor gamma and undergo apoptosis upon exposure to PPARgamma ligands. **2004**, 113, 203-13		42
551	Peroxisome proliferator-activated receptors (PPARs) and associated transcription factors in colon cancer: reduced expression of PPARgamma-coactivator 1 (PGC-1). **2004**, 203, 25-33		81
550	Limited tumor growth (HT29) in vivo under RO205-2349 is due to increased apoptosis and reduced cell volume but not to decreased proliferation rate. **2004**, 210, 7-15		4
549	Mitochondrial respiratory chain dysfunction, a non-receptor-mediated effect of synthetic PPAR-ligands: biochemical and pharmacological implications. **2004**, 319, 967-73		54
548	15-Lipoxygenase-1 has anti-tumorigenic effects in colorectal cancer. **2004**, 70, 7-15		62
547	PPARalpha agonists stimulate progastrin production in human colorectal carcinoma cells. **2004**, 120, 243-51		7
546	Activation of peroxisome proliferator-activated receptor-gamma reverses squamous metaplasia and induces transitional differentiation in normal human urothelial cells. **2004**, 164, 1789-98		76
545	Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. **2004**, 5, 419-29		377
544	Hepatitis B virus X protein modulates peroxisome proliferator-activated receptor gamma through protein-protein interaction. **2004**, 557, 73-80		26
543	Dietary long-chain n-3 fatty acids for the prevention of cancer: a review of potential mechanisms. **2004**, 79, 935-45		724
542	Oral preneoplasia and chemoprevention of squamous cell carcinoma of the head and neck. *Cancer Treatment and Research*, **2003**, 114, 61-83	3.5	
541	Activation and role of MAP kinases in 15d-PGJ2-induced apoptosis in the human pancreatic cancer cell line MIA PaCa-2. **2004**, 28, 153-9		30
540	Ligands of peroxisome proliferator-activated receptor gamma induce apoptosis in multiple myeloma. **2004**, 15, 955-60		32
539	PPAR trilogy from metabolism to cancer. *Current Opinion in Clinical Nutrition and Metabolic Care*, **2004**, 7, 397-402	3.8	28
538	The PAX8/PPAR gamma fusion oncogene as a potential therapeutic target in follicular thyroid carcinoma. **2004**, 4, 221-34		35

537	Activation of PPARgamma is required for curcumin to induce apoptosis and to inhibit the expression of extracellular matrix genes in hepatic stellate cells in vitro. *Biochemical Journal*, **2004**, 384, 149-57	3.8	100
536	Lysophosphatidic acid attenuates the cytotoxic effects and degree of peroxisome proliferator-activated receptor gamma activation induced by 15-deoxyDelta12,14-prostaglandin J2 in neuroblastoma cells. *Biochemical Journal*, **2004**, 382, 83-91	3.8	24
535	10 Role of Immunohistochemical Expression of Cyclooxygenase and Peroxisome Proliferator-Activated Receptor In Epithelial Ovarian Tumors. **2005**, 387-391		
534	Regulation of TRAIL-Induced Apoptosis by Transcriptional Factors. **2005**, 297-303		
533	PPARgamma as a therapeutic target for tumor angiogenesis and metastasis. **2005**, 4, 687-93		108
532	Expression and activation of peroxisome proliferator-activated receptors in growth plate chondrocytes. **2005**, 23, 1139-45		21
531	Ligands for the peroxisome proliferator-activated receptor-gamma have inhibitory effects on growth of human neuroblastoma cells in vitro. **2005**, 213, 157-68		30
530	Influence of the C161T but not Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma on colorectal cancer in an Indian population. **2005**, 96, 507-12		37
529	Review article: the potential of combinational regimen with non-steroidal anti-inflammatory drugs in the chemoprevention of colorectal cancer. **2005**, 21, 321-39		39
528	What is the contribution of a Kozak SNP in the CD40 gene to GravesPdisease?. **2005**, 62, 258		17
527	DHEA levels in treated CushingP disease may contribute to low quality of life. **2005**, 62, 258-9		5
526	Pre-operative medical therapy with rosiglitazone in two patients with newly diagnosed pituitary-dependent CushingP syndrome. **2005**, 62, 259-61		22
525	Clinical application of rhTSH in differentiated thyroid cancer: the facts and the questions. **2005**, 62, 261-2		2
524	Peroxisome proliferator-activated receptor-gamma (PPAR(gamma)) inhibits tumorigenesis by reversing the undifferentiated phenotype of metastatic non-small-cell lung cancer cells (NSCLC). **2005**, 24, 1412-22		98
523	The peroxisome proliferator-activated receptor gamma ligand rosiglitazone delays the onset of inflammatory bowel disease in mice with interleukin 10 deficiency. **2005**, 11, 231-43		83
522	Peroxisome proliferator-activated receptor gamma ligands induce cell cycle arrest and apoptosis in human renal carcinoma cell lines. **2005**, 26, 753-61		64
521	Cyclooxygenase-2 and prostaglandin signaling in cholangiocarcinoma. **2005**, 1755, 135-50		31
520	Pivotal role of peroxisome proliferator-activated receptor gamma (PPARgamma) in regulation of erythroid progenitor cell proliferation and differentiation. **2005**, 33, 857-64		24

519	Suppression of colitis-related mouse colon carcinogenesis by a COX-2 inhibitor and PPAR ligands. **2005**, 5, 46		104
518	Down-regulation of peroxisome proliferator-activated receptor gamma in human cervical carcinoma. **2005**, 97, 365-73		33
517	Activation of peroxisome proliferator-activated receptor-gamma by troglitazone (TGZ) inhibits human lung cell growth. **2005**, 96, 760-74		59
516	Dietary fat, fatty acid composition and risk of cancer. **2005**, 107, 540-559		11
515	Peroxisome proliferator-activated receptor gamma agonist troglitazone induces colon tumors in normal C57BL/6J mice and enhances colonic carcinogenesis in Apc1638 N/+ Mlh1+/- double mutant mice. **2005**, 116, 495-9		62
514	A high-fat diet generates alterations in nuclear receptor expression: prevention by vitamin A and links with cyclooxygenase-2 and beta-catenin. **2005**, 116, 839-46		23
513	The effect of PPARgamma ligands on UV- or chemically-induced carcinogenesis in mouse skin. **2005** , 43, 198-206		23
512	A new therapeutic approach in patients with advanced sarcoma. **2005**, 10, 438-40		10
511	Multi-site therapeutic modalities for inflammatory bowel diseases mechanisms of action. **2003**, 523-551		
510	Peroxisome proliferator-activated receptors and their relevance to dermatology. **2005**, 85, 194-202		30
509	New indications for established drugs: combined tumor-stroma-targeted cancer therapy with PPARgamma agonists, COX-2 inhibitors, mTOR antagonists and metronomic chemotherapy. *Current Cancer Drug Targets*, **2005**, 5, 393-419	2.8	50
508	Repression of beta-catenin function in malignant cells by nonsteroidal antiinflammatory drugs. **2005**, 102, 18567-71		71
507	Peroxisome proliferator-activated receptor delta and gamma agonists differentially alter tumor differentiation and progression during mammary carcinogenesis. **2005**, 65, 3950-7		89
506	15-deoxy-Delta12,14 prostaglandin J2 up-regulates Kruppel-like factor 4 expression independently of peroxisome proliferator-activated receptor gamma by activating the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase signal transduction pathway in HT-29 colon cancer cells. **2005**, 65, 4203-13		46
505	Significance of anti-inflammatory effects of PPARgamma agonists?. **2006**, 55, 1067-9		12
504	Recurrence rates in Crohn's disease: predicting the future and predicting the past. **2006**, 55, 1069-70		18
503	Critical role of peroxisome proliferator-activated receptor gamma on anoikis and invasion of squamous cell carcinoma. *Clinical Cancer Research*, **2005**, 11, 4012-21	12.9	47
502	Estrogen receptor alpha binds to peroxisome proliferator-activated receptor response element and negatively interferes with peroxisome proliferator-activated receptor gamma signaling in breast cancer cells. *Clinical Cancer Research*, **2005**, 11, 6139-47	12.9	117

501	Activation of mitogen-activated protein kinases by peroxisome proliferator-activated receptor ligands: an example of nongenomic signaling. **2005**, 68, 933-41		86
500	BP-1107 [{2-[4-(2,4-dioxo-thiazolidin-5-ylmethyl)-phenoxy]-ethyl}-methyl-amide]: a novel synthetic thiazolidinedione that inhibits epidermal hyperplasia in psoriatic skin-severe-combined immunodeficient mouse transplants after topical application. **2005**, 315, 996-1004		11
499	Action of thiazolidinediones on differentiation, proliferation and apoptosis of normal and transformed thyrocytes in culture. **2005**, 12, 291-303		61
498	Thiazolidinediones inhibit growth and invasiveness of the human adrenocortical cancer cell line H295R. **2005**, 90, 1332-9		62
497	Multiple signaling pathways converge on beta-catenin in thyroid cancer. **2005**, 15, 551-61		44
496	Evaluation of peroxisome proliferator-activated receptor-gamma expression in benign and malignant thyroid pathologies. **2005**, 15, 997-1003		20
495	Molecular Basis of Thyroid Cancer. *Cancer Treatment and Research*, **2005**,	3.5	1
494	Peroxisome proliferator-activated receptor gamma agonists promote TRAIL-induced apoptosis by reducing survivin levels via cyclin D3 repression and cell cycle arrest. **2005**, 280, 6742-51		86
493	A novel peroxisome proliferator-activated receptor gamma isoform with dominant negative activity generated by alternative splicing. **2005**, 280, 26517-25		46
492	Hic-5 regulates an epithelial program mediated by PPARgamma. *Genes and Development*, **2005**, 19, 362-75	12.6	82
491	The Wnt/beta-catenin signaling pathway targets PPARgamma activity in colon cancer cells. **2005**, 102, 1460-5		125
490	Interactions of peroxisome proliferator-activated receptor {gamma} and diet in etiology of colorectal cancer. **2005**, 14, 1224-9		31
489	Peroxisome proliferator-activated receptor gamma inhibition prevents adhesion to the extracellular matrix and induces anoikis in hepatocellular carcinoma cells. **2005**, 65, 2251-9		96
488	Role of nuclear receptors in lung tumourigenesis. **2005**, 41, 2561-8		29
487	Activation of PPARgamma is not involved in butyrate-induced epithelial cell differentiation. **2005**, 310, 196-204		13
486	Peroxisome proliferator-activated receptor expression and activation in normal human colonic epithelial cells and tubular adenomas. **2005**, 40, 198-205		42
485	Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPARgamma. **2005**, 65, 1561-9		188
484	Flavones suppress the expression of the high-affinity IgE receptor FcepsilonRI in human basophilic KU812 cells. **2005**, 53, 1812-7		35

483	Activation of PPAR{gamma} by curcumin inhibits Moser cell growth and mediates suppression of gene expression of cyclin D1 and EGFR. *American Journal of Physiology - Renal Physiology*, **2005**, 288, G447-56	5.1	109
482	The methyltransferase inhibitor 5-aza-2-deoxycytidine induces apoptosis via induction of 15-lipoxygenase-1 in colorectal cancer cells. *Molecular Cancer Therapeutics*, **2005**, 4, 1740-6	6.1	37
481	Selective activation of PPARgamma in breast, colon, and lung cancer cell lines. **2005**, 235, 21-9		64
480	Involvement of MEK-ERK signaling pathway in the inhibition of cell growth by troglitazone in human pancreatic cancer cells. **2005**, 332, 89-94		34
479	Increased expression of PPARgamma in high fat diet-induced liver steatosis in mice. **2005**, 336, 215-22		288
478	The many faces of PPARgamma. **2005**, 123, 993-9		1114
477	15d-PGJ2: the anti-inflammatory prostaglandin?. **2005**, 114, 100-9		260
476	Ciglitazone induces early cellular proliferation and NF-kappaB transcriptional activity in colon cancer cells through p65 phosphorylation. **2005**, 37, 645-54		16
475	The PPAR(gamma) K422Q mutation does not contribute to troglitazone inefficiency in colon cancer treatment. **2005**, 224, 111-6		7
474	PPAR-gamma activation inhibits angiogenesis by blocking ELR+CXC chemokine production in non-small cell lung cancer. *Neoplasia*, **2005**, 7, 294-301	6.4	85
473	Troglitazone, the peroxisome proliferator-activated receptor-gamma agonist, induces antiproliferation and redifferentiation in human thyroid cancer cell lines. **2005**, 15, 222-31		85
472	Treatment of thyroid cancer with histone deacetylase inhibitors and peroxisome proliferator-activated receptor-gamma agonists. **2005**, 15, 594-9		21
471	Death Receptors in Cancer Therapy. **2005**,		3
470	Cellular and molecular consequences of peroxisome proliferator-activated receptor-gamma activation in ovarian cancer cells. *Neoplasia*, **2006**, 8, 851-61	6.4	40
469	Thiazolidinediones: potential as therapeutics for psoriasis and perhaps other hyperproliferative skin disease. **2006**, 15, 1453-68		11
468	Control of peroxisome proliferator-activated receptor fate by the ubiquitinproteasome system. **2006**, 26, 679-92		20
467	Proline oxidase, a proapoptotic gene, is induced by troglitazone: evidence for both peroxisome proliferator-activated receptor gamma-dependent and -independent mechanisms. **2006**, 281, 2044-52		78
466	Peroxisome proliferator-activated receptor gamma regulates expression of signal transducer and activator of transcription 5A. **2006**, 312, 1371-80		13

465	Peroxisome proliferator-activated receptor gamma agonists: their role as vasoprotective agents in diabetes. **2006**, 35, 561-74, ix		22
464	1,1-Bis(3Pindolyl)-1-(p-substituted phenyl)methanes inhibit colon cancer cell and tumor growth through PPARgamma-dependent and PPARgamma-independent pathways. *Molecular Cancer Therapeutics*, **2006**, 5, 1362-70	6.1	47
463	1,1-Bis(3Pindolyl)-1-(p-substituted phenyl)methanes inhibit ovarian cancer cell growth through peroxisome proliferator-activated receptor-dependent and independent pathways. *Molecular Cancer Therapeutics*, **2006**, 5, 2324-36	6.1	31
462	In vitro and in vivo effects of the PPAR-alpha agonists fenofibrate and retinoic acid in endometrial cancer. **2006**, 5, 13		67
461	Bioassay for the identification of natural product-based activators of peroxisome proliferator-activated receptor-gamma (PPARgamma): the marine sponge metabolite psammaplin A activates PPARgamma and induces apoptosis in human breast tumor cells. **2006**, 69, 547-52		39
460	Up-regulation of ADRP in fatty liver in human and liver steatosis in mice fed with high fat diet. **2006** , 340, 1111-8		130
459	Phorbol ester potentiates the growth inhibitory effects of troglitazone via up-regulation of PPARgamma in A549 cells. **2006**, 349, 660-7		13
458	Cyclooxygenase-2 in hepatocellular carcinoma. **2006**, 32, 28-44		99
457	Quantitative analysis of PPARdelta mRNA by real-time RT-PCR in 86 rectal cancer tissues. **2006**, 32, 181-5		18
456	RS5444, a novel PPARgamma agonist, regulates aspects of the differentiated phenotype in nontransformed intestinal epithelial cells. **2006**, 251, 17-32		24
455	From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. **2006**, 45, 120-59		564
454	Synthesis and evaluation of a bromine-76-labeled PPARgamma antagonist 2-bromo-5-nitro-N-phenylbenzamide. **2006**, 33, 847-54		17
453	Protection of RPE cells from oxidative injury by 15-deoxy-delta12,14-prostaglandin J2 by augmenting GSH and activating MAPK. **2006**, 47, 5098-105		53
452	Relation between common polymorphisms in genes related to inflammatory response and colorectal cancer. *World Journal of Gastroenterology*, **2006**, 12, 5037-43	5.6	108
451	CDK5 is a novel regulatory protein in PPAR□ligand-induced antiproliferation. **2006**, 28, 191		1
450	Peroxisome-proliferator-activated receptor alpha agonists inhibit cyclo-oxygenase 2 and vascular endothelial growth factor transcriptional activation in human colorectal carcinoma cells via inhibition of activator protein-1. *Biochemical Journal*, **2006**, 395, 81-8	3.8	67
449	Genetic analysis of peroxisome proliferator-activated receptor □ splice variants in human colorectal cell lines. **2006**, 29, 1601		
448	Anti-proliferative effect of peroxisome proliferator-activated receptor gamma agonists on human malignant melanoma cells in vitro. **2006**, 17, 325-32		29

447	The long and winding road to gut homeostasis. **2006**, 22, 349-53	9
446	Peroxisome proliferator-activated receptor-gamma ligands inhibit proliferation and induce apoptosis in mantle cell lymphoma. **2006**, 17, 763-9	21
445	High-level Skp2 expression in pancreatic ductal adenocarcinoma: correlation with the extent of lymph node metastasis, higher histological grade, and poorer patient outcome. **2006**, 32, 376-81	35
444	PPARs: Lipid Sensors that Regulate Cell Differentiation Processes. **2006**, 117-131	
443	[Decreased PPARs activity mediated induction of anoikis and inability of cell adhesion and invasion in colorectal carcinoma cells]. **2006**, 128, 231-4	
442	Abnormal expression of PPAR gamma isoforms in the subcutaneous adipose tissue of patients with Cushingβ disease. **2007**, 66, 7-12	1
441	Meat, milk, saturated fatty acids, the Pro12Ala and C161T polymorphisms of the PPARgamma gene and colorectal cancer risk in Japanese. **2006**, 97, 1226-35	23
440	Systematic review: Cyclo-oxygenase-2 in human oesophageal adenocarcinogenesis. **2006**, 24, 1321-31	15
439	The mighty mouse: genetically engineered mouse models in cancer drug development. **2006**, 5, 741-54	483
438	Absence of the steroid receptor coactivator-3 induces B-cell lymphoma. **2006**, 25, 2453-64	53
437	Oxidative metabolism of linoleic acid modulates PPAR-beta/delta suppression of PPAR-gamma activity. **2006**, 25, 1225-41	89
436	PPARgamma insufficiency promotes follicular thyroid carcinogenesis via activation of the nuclear factor-kappaB signaling pathway. **2006**, 25, 2736-47	89
435	Peroxisome proliferator-activated receptor gamma in malignant diseases. **2006**, 58, 1-14	101
434	Effect of diabetes mellitus on the epidemiology and outcomes of colon cancer. **2006**, 23, 515-9	25
433	A Ligand for peroxisome proliferator-activated receptor gamma inhibits human cholangiocarcinoma cell growth: potential molecular targeting strategy for cholangioma. **2006**, 51, 1650-7	8
432	PPARgamma and colon and rectal cancer: associations with specific tumor mutations, aspirin, ibuprofen and insulin-related genes (United States). **2006**, 17, 239-49	41
431	15-deoxy-(Delta12,14)-prostaglandin J2 (15d-PGJ2) induces cell death through caspase-independent mechanism in A172 human glioma cells. **2006**, 31, 1247-54	26
430	Manganese treatment modulates the expression of peroxisome proliferator-activated receptors in astrocytoma and neuroblastoma cells. **2006**, 31, 1305-16	15

429	Pioglitazone, a synthetic ligand for PPARgamma, induces apoptosis in RB-deficient human colorectal cancer cells. **2006**, 11, 401-11		35
428	NF-kappaB/PPAR gamma and/or AP-1/PPAR gamma P on/off P switches and induction of CBP in colon adenocarcinomas: correlation with COX-2 expression. **2007**, 22, 57-68		39
427	PPAR-gamma is expressed and NF-kB pathway is activated and correlates positively with COX-2 expression in stromal myofibroblasts surrounding colon adenocarcinomas. **2006**, 132, 76-84		63
426	Cyanidin attenuates PGE2 production and cyclooxygenase-2 expression in LNCaP human prostate cancer cells. **2006**, 17, 589-96		55
425	Expression patterns of the chicken peroxisome proliferator-activated receptors (PPARs) during the development of the digestive organs. **2006**, 6, 171-9		15
424	Peroxisome proliferator-activated receptor gamma and spermidine/spermine N1-acetyltransferase gene expressions are significantly correlated in human colorectal cancer. **2006**, 6, 191		28
423	PPARgamma-independent induction of growth arrest and apoptosis in prostate and bladder carcinoma. **2006**, 6, 53		71
422	Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo. **2006**, 43, 134-43		109
421	Intestinal-specific PPARgamma deficiency enhances tumorigenesis in ApcMin/+ mice. **2006**, 119, 2339-46		65
420	The toxicology of ligands for peroxisome proliferator-activated receptors (PPAR). **2006**, 90, 269-95		217
419	Conjugated linoleic acid stimulates an anti-tumorigenic protein NAG-1 in an isomer specific manner. **2006**, 27, 972-81		107
418	Obesity, peroxisome proliferator-activated receptor, and atherosclerosis in type 2 diabetes. **2006**, 26, 28-40		104
417	Epithelial cell PPAR[gamma] contributes to normal lung maturation. **2006**, 20, 1507-9		85
416	A novel peroxisome proliferator-activated receptor gamma ligand, MCC-555, induces apoptosis via posttranscriptional regulation of NAG-1 in colorectal cancer cells. *Molecular Cancer Therapeutics*, **2006**, 5, 1352-61	6.1	57
415	Beyond peroxisome proliferator-activated receptor gamma signaling: the multi-facets of the antitumor effect of thiazolidinediones. **2006**, 13, 401-13		102
414	PPARgamma as a new therapeutic target in inflammatory bowel diseases. **2006**, 55, 1341-9		295
413	15-deoxy-Delta12,14-prostaglandin J2 inhibits the expression of microsomal prostaglandin E synthase type 2 in colon cancer cells. **2006**, 47, 1071-80		13
412	Inhibition of in vivo glioma growth and invasion by peroxisome proliferator-activated receptor gamma agonist treatment. **2006**, 70, 1524-33		89

411	Genetics and Epigenetics in Cancer Biology. **2006**, 25-56		1
410	Function of PPARgamma and its ligands in lung cancer. **2006**, 43, 183-202		23
409	Attenuation of peroxisome proliferator-activated receptor gamma (PPARgamma) mediates gastrin-stimulated colorectal cancer cell proliferation. **2006**, 281, 14700-10		25
408	9-cis-retinoic acid up-regulates expression of transcriptional coregulator PELP1, a novel coactivator of the retinoid X receptor alpha pathway. **2006**, 281, 15394-404		14
407	Overcoming diabetes-induced hyperglycemia through inhibition of hepatic phosphoenolpyruvate carboxykinase (GTP) with RNAi. **2006**, 13, 401-10		61
406	The potential of antidiabetic thiazolidinediones for anticancer therapy. **2006**, 15, 1039-49		39
405	Clofibric acid, a peroxisome proliferator-activated receptor alpha ligand, inhibits growth of human ovarian cancer. *Molecular Cancer Therapeutics*, **2007**, 6, 1379-86	6.1	71
404	Thyroid hormone receptor mutations and disease: insights from knock-in mouse models. **2007**, 2, 47-57		2
403	Role of PPARs and Retinoid X Receptors in the Regulation of Lung Maturation and Development. **2007**, 2007, 91240		18
402	Peroxisome proliferator-activated receptor gamma agonists inhibit the proliferation and invasion of human colon cancer cells. **2007**, 83, 414-9		42
401	Differential expression, distribution, and function of PPAR-gamma in the proximal and distal colon. **2007**, 30, 342-53		48
400	Biology of PPAR gamma in cancer: a critical review on existing lacunae. **2007**, 7, 532-40		94
399	Long-term treatment of central Cushing's syndrome with rosiglitazone. **2007**, 115, 292-7		20
398	The effect of rosiglitazone on orthostatic tolerance during heat exposure in individuals with type II diabetes. **2007**, 9, 377-86		15
397	15-deoxy-Delta12,14-prostaglandin J2 inhibits transcriptional activity of estrogen receptor-alpha via covalent modification of DNA-binding domain. **2007**, 67, 2595-602		44
396	Suppression of N-nitrosobis(2-oxopropyl)amine-induced pancreatic carcinogenesis in hamsters by pioglitazone, a ligand of peroxisome proliferator-activated receptor gamma. **2007**, 28, 1692-6		24
395	Synergistic effects of RXR alpha and PPAR gamma ligands to inhibit growth in human colon cancer cells--phosphorylated RXR alpha is a critical target for colon cancer management. **2007**, 56, 1557-63		73
394	Expression of a peroxisome proliferator-activated receptor gamma 1 splice variant that was identified in human lung cancers suppresses cell death induced by cisplatin and oxidative stress. *Clinical Cancer Research*, **2007**, 13, 2577-83	12.9	28

393	Peroxisome proliferator-activated receptors in lung cancer. **2007**, 2007, 90289		16
392	Expression of adipose differentiation-related protein: a predictor of cancer-specific survival in clear cell renal carcinoma. *Clinical Cancer Research*, **2007**, 13, 152-60	12.9	61
391	Peroxisome proliferator-activated receptor and ligands inhibit the growth of human ovarian cancer. **2007**, 18, 833		3
390	Low expression of ORF4, a dominant negative variant of peroxisome proliferator-activated receptor in colorectal adenocarcinoma. **2007**, 18, 489		
389	A peroxisome proliferator-activated receptor antagonist induces vimentin cleavage and inhibits invasion in high-grade hepatocellular carcinoma. **2007**,		0
388	Prolonged survival of mice with established intracerebral glioma receiving combined treatment with peroxisome proliferator-activated receptor-gamma thiazolidinedione agonists and interleukin-2-secreting syngeneic/allogeneic fibroblasts. **2007**, 106, 299-305		15
387	Peroxisome proliferator-activated receptor gamma: a novel target for cancer therapeutics?. **2007**, 18, 237-44		104
386	Peroxisome proliferator-activated receptor gamma (PPARgamma) regulates trefoil factor family 2 (TFF2) expression in gastric epithelial cells. **2007**, 39, 626-37		15
385	Pro-MMP-2 activation by the PPARgamma agonist, ciglitazone, induces cell invasion through the generation of ROS and the activation of ERK. **2007**, 581, 3303-10		41
384	Activation of peroxisome proliferator-activated receptor gamma contributes to the survival of T lymphoma cells by affecting cellular metabolism. **2007**, 170, 722-32		24
383	9trans,11trans conjugated linoleic acid inhibits the development of azoxymethane-induced colonic aberrant crypt foci in rats. **2007**, 59, 82-91		18
382	Targeting mitochondria in the treatment of human cancer: a coordinated attack against cancer cell energy metabolism and signalling. **2007**, 11, 1055-69		24
381	15-deoxy-Delta 12,14-ProstaglandinJ2 regulates dedifferentiation through peroxisome proliferator-activated receptor-gamma-dependent pathway but not COX-2 expression in articular chondrocytes. **2007**, 22, 891-7		5
380	PPARgamma inhibitors reduce tubulin protein levels by a PPARgamma, PPARdelta and proteasome-independent mechanism, resulting in cell cycle arrest, apoptosis and reduced metastasis of colorectal carcinoma cells. **2007**, 120, 702-13		47
379	EP1-4 subtype, COX and PPAR gamma receptor expression in colorectal cancer in prediction of disease-specific mortality. **2007**, 121, 232-40		56
378	Present concepts and future outlook: function of peroxisome proliferator-activated receptors (PPARs) for pathogenesis, progression, and therapy of cancer. **2007**, 212, 1-12		81
377	Inhibitory effect of meloxicam, a selective cyclooxygenase-2 inhibitor, and ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, on the growth of human ovarian cancers. **2007**, 110, 791-800		53
376	Synthesis of O-prenylated and O-geranylated derivatives of 5-benzylidene2,4-thiazolidinediones and evaluation of their free radical scavenging activity as well as effect on some phase II antioxidant/detoxifying enzymes. **2007**, 17, 1149-54		44

375	Activation of peroxisome proliferator-activated receptor gamma inhibits cell growth via apoptosis and arrest of the cell cycle in human colorectal cancer. **2007**, 8, 82-8	39
374	Expression of peroxisome proliferator-activated receptor gamma (PPAR-gamma) in canine nasal carcinomas. **2007**, 54, 406-10	8
373	Antiproliferative effect of conjugated linoleic acid in caco-2 cells: involvement of PPARgamma and APC/beta-catenin pathways. **2007**, 169, 110-21	17
372	Synergy between PPARgamma ligands and platinum-based drugs in cancer. **2007**, 11, 395-406	112
371	15-Deoxy-delta(12,14)-prostaglandin J(2) down-regulates CXCR4 on carcinoma cells through PPARgamma- and NFkappaB-mediated pathways. **2007**, 313, 3446-58	17
370	Expression of peroxisome proliferator-activated receptor-gamma in colon cancer: correlation with histopathological parameters, cell cycle-related molecules, and patientsPsurvival. **2007**, 52, 2305-11	35
369	Peroxisome proliferator-activated receptor gamma (PPARgamma) and colorectal carcinogenesis. **2007**, 133, 917-28	33
368	Ciglitazone induces caspase-independent apoptosis through down-regulation of XIAP and survivin in human glioma cells. **2008**, 33, 551-61	30
367	PPAR-gamma ligand promotes the growth of APC-mutated HT-29 human colon cancer cells in vitro and in vivo. **2008**, 26, 283-8	29
366	Structure and physiological functions of the human peroxisome proliferator-activated receptor gamma. **2008**, 56, 331-45	80
365	Nuclear receptors, intestinal architecture and colon cancer: an intriguing link. **2008**, 65, 1523-43	47
364	Effect of activation of PPAR□on cell cycle progression in human gastric carcinoma cells. **2008**, 7, 534-537	
363	Loss of XIAP sensitizes rosiglitazone-induced growth inhibition of colon cancer in vivo. **2008**, 122, 2858-63	31
362	The high affinity peroxisome proliferator-activated receptor-gamma agonist RS5444 inhibits both initiation and progression of colon tumors in azoxymethane-treated mice. **2008**, 123, 991-7	11
361	Basic evidence of molecular targeted therapy for oral cancer and salivary gland cancer. **2008**, 30, 800-9	55
360	Expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor gamma during malignant melanoma progression. **2008**, 35, 989-94	31
359	Synergistic effect of 15-lipoxygenase 2 and radiation in killing head-and-neck cancer. **2008**, 15, 323-30	8
358	Primary chemoprevention of endometrial hyperplasia with the peroxisome proliferator-activated receptor gamma agonist rosiglitazone in the PTEN heterozygote murine model. **2008**, 18, 329-38	14

357	Role of peroxisome proliferator-activated receptor-gamma (PPARgamma) during liver regeneration in rats. **2008**, 23, 930-7		30
356	PGJ2 antagonizes NF-kappaB-induced HIV-1 LTR activation in colonic epithelial cells. **2008**, 380, 1-11		12
355	Deoxyelephantopin inhibits cancer cell proliferation and functions as a selective partial agonist against PPARgamma. **2008**, 75, 1381-92		33
354	A novel benzotriazole derivative inhibits proliferation of human hepatocarcinoma cells by increasing oxidative stress concomitant mitochondrial damage. **2008**, 584, 144-52		16
353	Modulation of cell growth and PPARgamma expression in human colorectal cancer cell lines by ciglitazone. **2008**, 60, 505-12		9
352	Structural basis for catalytic and inhibitory mechanisms of human prostaglandin reductase PTGR2. **2008**, 16, 1714-23		32
351	Peroxisome proliferator-activated receptors (PPARs) and the human skin: importance of PPARs in skin physiology and dermatologic diseases. **2008**, 9, 15-31		95
350	Thiazolidinedione therapy is not associated with increased colonic neoplasia risk in patients with diabetes mellitus. **2008**, 135, 1914-23, 1923.e1		19
349	Cancer incidence among patients treated with antidiabetic pharmacotherapy. **2008**, 2, 47-57		59
348	Loss of XIAP sensitizes colon cancer cells to PPARgamma independent antitumor effects of troglitazone and 15-PGJ2. **2008**, 268, 260-71		28
347	Fat and beyond: the diverse biology of PPARgamma. **2008**, 77, 289-312		1484
346	Molecular Targeting in Hepatocellular Carcinoma. **2008**, 165-210		1
345	PPARgamma is involved in mesalazine-mediated induction of apoptosis and inhibition of cell growth in colon cancer cells. **2008**, 29, 1407-14		44
344	PPAR{gamma} accelerates cellular senescence by inducing p16INK4{alpha} expression in human diploid fibroblasts. *Journal of Cell Science*, **2008**, 121, 2235-45	5.3	71
343	CREB3L2-PPARgamma fusion mutation identifies a thyroid signaling pathway regulated by intramembrane proteolysis. **2008**, 68, 7156-64		52
342	A phase I study of bexarotene and rosiglitazone in patients with refractory cancers. **2008**, 54, 236-41		18
341	Peroxisome Proliferator-Activated Receptor-gamma Is a Potent Target for Prevention and Treatment in Human Prostate and Testicular Cancer. **2008**, 2008, 249849		29
340	The use of GEM models for experimental cancer therapeutics. **2008**, 1, 83-6		41

339	Nuclear receptors and inflammatory diseases. **2008**, 233, 496-506		57
338	Peroxisome proliferator-activated receptor gamma down-regulates follistatin in intestinal epithelial cells through SP1. **2008**, 283, 29784-94		19
337	Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin. *Clinical Cancer Research*, **2008**, 14, 6478-86	12.9	67
336	Urothelial carcinogenesis in the urinary bladder of rats treated with naveglitazar, a gamma-dominant PPAR alpha/gamma agonist: lack of evidence for urolithiasis as an inciting event. **2008**, 36, 218-31		35
335	Enterococcus faecalis from newborn babies regulate endogenous PPARgamma activity and IL-10 levels in colonic epithelial cells. **2008**, 105, 1943-8		104
334	Peroxisome proliferator-activated receptor ligand MCC-555 suppresses intestinal polyps in ApcMin/+ mice via extracellular signal-regulated kinase and peroxisome proliferator-activated receptor-dependent pathways. *Molecular Cancer Therapeutics*, **2008**, 7, 2779-87	6.1	20
333	Down-regulation of X-linked inhibitor of apoptosis synergistically enhanced peroxisome proliferator-activated receptor gamma ligand-induced growth inhibition in colon cancer. *Molecular Cancer Therapeutics*, **2008**, 7, 2203-11	6.1	20
332	Peroxisome proliferator-activated receptor gamma (PPARgamma) suppresses colonic epithelial cell turnover and colon carcinogenesis through inhibition of the beta-catenin/T cell factor (TCF) pathway. **2008**, 106, 627-38		21
331	Inhibition of peroxisome proliferator-activated receptor gamma promotes tumorigenesis through activation of the beta-catenin / T cell factor (TCF) pathway in the mouse intestine. **2008**, 108, 535-44		11
330	Peroxisome proliferator-activated receptor gamma and lung cancer biology: implications for therapy. **2008**, 56, 528-33		26
329	Potential Benefits of Glitazones for Cancer and Vascular Disease. **2008**, 3, 111-125		2
328	The roles of sPLA2-IIA (Pla2g2a) in cancer of the small and large intestine. **2008**, 13, 4144-74		30
327	PPARgamma1 as a molecular target of eicosapentaenoic acid in human colon cancer (HT-29) cells. **2008**, 138, 250-6		53
326	The Role of PPARs in Cancer. **2008**, 2008, 102737		154
325	Pathophysiological Roles of PPARgamma in Gastrointestinal Epithelial Cells. **2008**, 2008, 148687		4
324	Synergistic Effects of PPARgamma Ligands and Retinoids in Cancer Treatment. **2008**, 2008, 181047		32
323	The Critical Role of PPARgamma in Human Malignant Melanoma. **2008**, 2008, 503797		5
322	PPAR-gamma Thiazolidinedione Agonists and Immunotherapy in the Treatment of Brain Tumors. **2008**, 2008, 547470		8

321	PPARgamma: The Portrait of a Target Ally to Cancer Chemopreventive Agents. **2008**, 2008, 436489	6
320	A Novel Mechanism of PPARgamma Regulation of TGFbeta1: Implication in Cancer Biology. **2008**, 2008, 762398	8
319	Role of peroxisome proliferator-activated receptor gamma and its ligands in the treatment of hematological malignancies. **2008**, 2008, 834612	19
318	To Live or to Die: Prosurvival Activity of PPARgamma in Cancers. **2008**, 2008, 209629	9
317	PPARgamma and PPARdelta as Modulators of Neoplasia and Cell Fate. **2008**, 2008, 247379	16
316	PPARgamma and Agonists against Cancer: Rational Design of Complementation Treatments. **2008**, 2008, 945275	14
315	Clinical Use of PPARgamma Ligands in Cancer. **2008**, 2008, 159415	27
314	PPAR Ligands for Cancer Chemoprevention. **2008**, 2008, 548919	16
313	Peroxisome proliferator-activated receptors and progression of colorectal cancer. **2008**, 2008, 931074	22
312	A Role for PPARgamma in the Regulation of Cytokines in Immune Cells and Cancer. **2008**, 2008, 961753	28
311	Underexpression of PPARgamma is associated with aneuploidy and lower differentiation of thyroid tumours of follicular origin. **2009**, 22, 907-13	5
310	The PPAR Agonist Rosiglitazone Inhibits Glioma Cell Proliferation and Migrationin vitroand Glioma Tumor Growthin vivo. **2009**, 18, 112	
309	Review paper: Cancer chemopreventive compounds and canine cancer. **2009**, 46, 576-88	15
308	Multiple myeloma cells undergo differentiation upon exposure to rosiglitazone and all-trans retinoic acid. **2009**, 50, 966-73	5
307	Caspase-mediated cleavage of beta-catenin precedes drug-induced apoptosis in resistant cancer cells. **2009**, 284, 13577-13588	26
306	Neoplastic and non-neoplastic changes in F-344 rats treated with Naveglitazar, a gamma-dominant PPAR alpha/gamma agonist. **2009**, 37, 741-53	19
305	Chemical genomics of cancer chemopreventive dithiolethiones. **2009**, 30, 480-6	21
304	Thiazolidinediones induce proliferation of human bronchial epithelial cells through the GPR40 receptor. **2009**, 296, L970-8	32

303	Activation of PPARgamma by rosiglitazone attenuates intestinal Cl- secretion. *American Journal of Physiology - Renal Physiology*, **2009**, 297, G82-9	5.1	19
302	Current understanding of the role of PPAR□ in gastrointestinal cancers. **2009**, 2009, 816957		8
301	Repression of NHE1 expression by PPARgamma activation is a potential new approach for specific inhibition of the growth of tumor cells in vitro and in vivo. **2009**, 69, 8636-44		55
300	Peroxisome proliferator-activated receptor-gamma contributes to the inhibitory effects of Embelin on colon carcinogenesis. **2009**, 69, 4776-83		66
299	All-trans retinoic acid can intensify the growth inhibition and differentiation induction effect of rosiglitazone on multiple myeloma cells. **2009**, 83, 191-202		10
298	KLF4-dependent, PPARgamma-induced expression of GPA33 in colon cancer cell lines. **2009**, 125, 2802-9		35
297	Differential effects of PPARgamma activation by the oral antidiabetic agent pioglitazone in Barrett□ carcinoma in vitro and in vivo. **2009**, 44, 919-29		10
296	The simultaneous expression of peroxisome proliferator-activated receptor delta and cyclooxygenase-2 may enhance angiogenesis and tumor venous invasion in tissues of colorectal cancers. **2009**, 54, 1108-14		17
295	Secretome-based proteomics reveals sulindac-modulated proteins released from colon cancer cells. **2009**, 3, 433-51		29
294	Peroxisome proliferator-activated receptor gamma agonists potentiate the cytotoxic effect of valproic acid in multiple myeloma cells. **2009**, 147, 662-71		14
293	Troglitazone inhibits cell proliferation by attenuation of epidermal growth factor receptor signaling independent of peroxisome proliferator-activated receptor gamma. **2009**, 19, 720-32		20
292	In vitro and in vivo anti-melanoma effects of ciglitazone. **2009**, 129, 1208-18		43
291	Substituent effect on the emission behavior of thiazolidinedione derivatives in cationic and anionic micellar media. **2009**, 329, 160-6		3
290	Role of hydrogen bonding on the spectroscopic properties of thiazolidinedione derivatives in homogeneous solvents. **2009**, 72, 1097-102		14
289	Obesity and cancer: the role of dysfunctional adipose tissue. **2009**, 18, 2569-78		515
288	PPARgamma activation induces autophagy in breast cancer cells. **2009**, 41, 2334-42		87
287	Troglitazone increases expression of E-cadherin and claudin 4 in human pancreatic cancer cells. **2009**, 380, 614-9		11
286	Friend or foe? Role of peroxisome proliferator-activated receptor-gamma in human bladder cancer. **2009**, 27, 585-91		15

285	Colorectal cancer expression of peroxisome proliferator-activated receptor gamma (PPARG, PPARgamma) is associated with good prognosis. **2009**, 136, 1242-50	117
284	PPARG: a new independent marker for colorectal cancer survival. **2009**, 136, 1157-60	9
283	Transcription factors Krüppel-like factor 6 and peroxisome proliferator-activated receptor-{gamma} mediate high glucose-induced thioredoxin-interacting protein. **2009**, 175, 1858-67	41
282	Telmisartan as a peroxisome proliferator-activated receptor-γ ligand is a new target in the treatment of human renal cell carcinoma. **2009**, 2, 193-8	22
281	Quantitative PCR. 39-61	2
280	Activating peroxisome proliferator-activated receptor gamma mutant promotes tumor growth in vivo by enhancing angiogenesis. **2009**, 69, 9236-44	38
279	Type 2 diabetes and cancer: what is the connection?. **2010**, 77, 197-213	56
278	Transglutaminase-dependent antiproliferative and differentiative properties of nimesulide on B16-F10 mouse melanoma cells. **2010**, 38, 257-62	23
277	PPARgamma ligands inhibit telomerase activity and hTERT expression through modulation of the Myc/Mad/Max network in colon cancer cells. **2010**, 14, 1347-57	21
276	Distribution of peroxisome proliferator-activated receptor-gamma polymorphisms in Chinese and Dutch patients with inflammatory bowel disease. **2010**, 16, 312-9	18
275	Peroxisome proliferator-activated receptor gamma ligand-mediated apoptosis of hepatocellular carcinoma cells depends upon modulation of PI3Kinase pathway independent of Akt. **2010**, 5, 20	8
274	Mistletoe lectin-I augments antiproliferative effects of the PPARgamma agonist rosiglitazone on human malignant melanoma cells. **2010**, 24, 1354-8	7
273	Aiming drug discovery at lysophosphatidic acid targets. **2010**, 161, 241-70	131
272	In vitro and in vivo therapeutic efficacy of the PPAR-γ agonist troglitazone in combination with cisplatin against malignant pleural mesothelioma cell growth. **2010**, 101, 1955-64	17
271	The nuclear receptor PPARβ individually responds to serotonin- and fatty acid-metabolites. **2010**, 29, 3395-407	117
270	Enteric glia modulate epithelial cell proliferation and differentiation through 15-deoxy-12,14-prostaglandin J2. **2010**, 588, 2533-44	59
269	Disruption of PPARgamma signaling results in mouse prostatic intraepithelial neoplasia involving active autophagy. **2010**, 17, 469-81	45
268	[The effect of rosiglitazone on the cell proliferation and the expressions of p27 and skp2 in helicobacter pylori infected human gastric epithelial cells]. **2010**, 55, 225-31	2

267	Natural polyphenols as anti-inflammatory agents. **2010**, 2, 318-31		9
266	Negative regulation of the oncogenic transcription factor FoxM1 by thiazolidinediones and mithramycin. **2010**, 9, 1008-16		31
265	Chemopreventive effects of pioglitazone on chemically induced lung carcinogenesis in mice. *Molecular Cancer Therapeutics*, **2010**, 9, 3074-82	6.1	42
264	Peroxisome proliferator-activated receptor-gamma activation inhibits tumor metastasis by antagonizing Smad3-mediated epithelial-mesenchymal transition. *Molecular Cancer Therapeutics*, **2010**, 9, 3221-32	6.1	104
263	Molecular alterations associated with sulindac-resistant colon tumors in ApcMin/+ mice. **2010**, 3, 1187-97		14
262	Thyroid hormone receptors regulate adipogenesis and carcinogenesis via crosstalk signaling with peroxisome proliferator-activated receptors. **2010**, 44, 143-54		48
261	Induction of metastatic gastric cancer by peroxisome proliferator-activated receptor activation. **2010**, 2010, 571783		27
260	Therapeutic Implications of PPARgamma in Human Osteosarcoma. **2010**, 2010, 956427		33
259	PPARs in Irradiation-Induced Gastrointestinal Toxicity. **2010**, 2010, 528327		5
258	Gastrointestinal Cytoprotection by PPAR Ligands. **2010**, 2010,		2
257	PPARs in Human Neuroepithelial Tumors: PPAR Ligands as Anticancer Therapies for the Most Common Human Neuroepithelial Tumors. **2010**, 2010, 427401		9
256	Drug efficacy testing in mice. **2012**, 355, 19-38		10
255	PPARgamma activation extinguishes smoking carcinogen by inhibiting NNK-mediated proliferation. **2010**, 42, 113-22		14
254	Peroxisome proliferator-activated receptor-gamma inhibits transformed growth of non-small cell lung cancer cells through selective suppression of Snail. *Neoplasia*, **2010**, 12, 224-34	6.4	30
253	Therapeutic potential of peroxisome proliferator-activated receptors in chronic inflammation and colorectal cancer. **2010**, 39, 697-707		15
252	IGFBP-rP1, a potential molecule associated with colon cancer differentiation. **2010**, 9, 281		14
251	The intestinal nuclear receptor signature with epithelial localization patterns and expression modulation in tumors. **2010**, 138, 636-48, 648.e1-12		65
250	Natural product-inspired synthesis of thiazolidine and thiazolidinone compounds and their anticancer activities. **2010**, 16, 1826-42		42

249	Phospholipase D2-dependent inhibition of the nuclear hormone receptor PPARgamma by cyclic phosphatidic acid. **2010**, 39, 421-32		100
248	Bioenergetic pathways in tumor mitochondria as targets for cancer therapy and the importance of the ROS-induced apoptotic trigger. **2010**, 31, 29-59		132
247	Structural requirement for PPARgamma binding revealed by a meta analysis of holo-crystal structures. **2010**, 92, 499-506		4
246	15-Lipoxygenases and its metabolites 15(S)-HETE and 13(S)-HODE in the development of non-small cell lung cancer. **2010**, 65, 321-6		54
245	From Molecular to Modular Tumor Therapy. **2010**,		5
244	PPAR□disease gene network and identification of therapeutic targets for prostate cancer. **2011**, 19, 781-96		9
243	PPAR□a molecular link between systemic metabolic disease and benign prostate hyperplasia. **2011**, 82, 220-36		34
242	The roles of Kruppel-like factor 6 and peroxisome proliferator-activated receptor-□in the regulation of macrophage inflammatory protein-3□at early onset of diabetes. **2011**, 43, 383-92		25
241	Cytotoxicity of troglitazone through PPAR□ndependent pathway and p38 MAPK pathway in renal cell carcinoma. **2011**, 312, 219-27		31
240	New frontiers in the treatment of liposarcoma, a therapeutically resistant malignant cohort. **2011**, 14, 52-66		40
239	Curcumin suppresses proliferation and induces apoptosis in human biliary cancer cells through modulation of multiple cell signaling pathways. **2011**, 32, 1372-80		101
238	Metabolic alterations in cancer cells and therapeutic implications. **2011**, 30, 508-25		63
237	Vitamin B6 regulates mRNA expression of peroxisome proliferator-activated receptor-□target genes. **2011**, 2, 419-424		12
236	Identification of candidate small-molecule therapeutics to cancer by gene-signature perturbation in connectivity mapping. *PLoS ONE*, **2011**, 6, e16382	3.7	29
235	Evaluation of an extractionless high-performance liquid chromatography-tandem mass spectrometry method for detection and quantitation of rosiglitazone in canine plasma. **2011**, 72, 263-70		2
234	PPAR□potentiates anticancer effects of gemcitabine on human pancreatic cancer cells. **2012**, 40, 679-85		17
233	PPAR□s functionally expressed in clear cell renal cell carcinoma. **2011**, 38, 851-7		2
232	Peroxisome proliferator-activated receptors and cancer: challenges and opportunities. **2011**, 164, 68-82		96

231	Mycophenolic acid induces adipocyte-like differentiation and reversal of malignancy of breast cancer cells partly through PPAR. **2011**, 658, 1-8		22
230	Metabolic activities and probiotic potential of bifidobacteria. **2011**, 149, 88-105		166
229	Anticancer activity of thymoquinone in breast cancer cells: possible involvement of PPAR- pathway. **2011**, 82, 464-75		149
228	Peroxisome proliferator-activated receptor agonist pioglitazone inhibits catenin-mediated glioma cell growth and invasion. **2011**, 349, 1-10		32
227	Chromosome 3p alterations in pancreatic endocrine neoplasia. **2011**, 458, 39-45		14
226	Combination of ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, and cisplatin enhances the inhibition of growth of human ovarian cancers. **2011**, 137, 1219-28		30
225	15-lipoxygenase-1 exerts its tumor suppressive role by inhibiting nuclear factor-kappa B via activation of PPAR gamma. **2011**, 112, 2490-501		27
224	PPARPromotes Growth and Invasion of Thyroid Cancer Cells. **2011**, 2011, 171765		22
223	Synergistic interactions between heregulin and peroxisome proliferator-activated receptor-gamma (PPARgamma) agonist in breast cancer cells. **2011**, 286, 20087-99		8
222	Peroxisome proliferator-activated receptor-gamma coactivator 1-alpha (PGC1alpha) is a metabolic regulator of intestinal epithelial cell fate. **2011**, 108, 6603-8		106
221	The Role of PPARin the Transcriptional Control by Agonists and Antagonists. **2012**, 2012, 362361		20
220	Effects of PPARLigands on Leukemia. **2012**, 2012, 483656		13
219	Development of an inflammation-associated colorectal cancer model and its application for research on carcinogenesis and chemoprevention. **2012**, 2012, 658786		83
218	Anti- and Protumorigenic Effects of PPARin Lung Cancer Progression: A Double-Edged Sword. **2012**, 2012, 362085		5
217	Dietary conjugated linoleic acid activates PPARand the intestinal trefoil factor in SW480 cells and mice with dextran sulfate sodium-induced colitis. **2012**, 142, 2135-40		27
216	Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models. *Clinical Cancer Research*, **2012**, 18, 5290-303	12.9	110
215	Combination chemoprevention: future direction of colorectal cancer prevention. **2012**, 21, 231-40		21
214	Therapeutic Kinase Inhibitors. **2012**,		1

213	Di(2-ethylhexyl)phthalat (DEHP) [MAK Value Documentation in German language, 2002]. **2012**, 1-81		
212	Peroxisome proliferator-activated receptor confers resistance to peroxisome proliferator-activated receptor induced apoptosis in colorectal cancer cells. **2012**, 31, 1013-23		23
211	The role of peroxisome proliferator-activated receptors in colorectal cancer. **2012**, 2012, 876418		22
210	The role of peroxisome proliferator-activated receptors in the esophageal, gastric, and colorectal cancer. **2012**, 2012, 242498		19
209	Inhibitory effect of PPAR bn NR0B1 in tumorigenesis of lung adenocarcinoma. **2012**, 41, 1278-84		6
208	Retinoids: novel immunomodulators and tumour-suppressive agents?. **2012**, 167, 483-92		18
207	Role of PPARg2 transcription factor in thiazolidinedione-induced insulin sensitization. **2012**, 64, 161-71		32
206	Synthesis, characterization and biological evaluation of ureidofibrate-like derivatives endowed with peroxisome proliferator-activated receptor activity. **2012**, 55, 37-54		44
205	Synthesis and evaluation of 18F-labeled PPAR antagonists. **2012**, 39, 77-87		9
204	Priceless GEMMs: genetically engineered mouse models for colorectal cancer drug development. **2012**, 33, 449-55		30
203	Overview of human primary tumorgraft models: comparisons with traditional oncology preclinical models and the clinical relevance and utility of primary tumorgrafts in basic and translational oncology research. **2012**, Chapter 14, Unit 14.22		20
202	Overcoming challenges of ovarian cancer stem cells: novel therapeutic approaches. **2012**, 8, 994-1010		43
201	MiR-27b targets PPAR to inhibit growth, tumor progression and the inflammatory response in neuroblastoma cells. **2012**, 31, 3818-25		124
200	Preclinical cancer chemoprevention studies using animal model of inflammation-associated colorectal carcinogenesis. *Cancers*, **2012**, 4, 673-700	6.6	12
199	Di(2-ethylhexyl)phthalate (DEHP) [MAK Value Documentation, 2009]. **2012**, 78-164		
198	PPAR gamma, bioactive lipids, and cancer progression. **2012**, 17, 1816-34		70
197	A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies. **2012**, 118, 5403-13		46
196	The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention. **2012**, 12, 181-95		317

195	Chronic exposure to contaminated drinking water stimulates PPAR expression in mice livers. **2012**, 88, 407-12		5
194	Association of peroxisome proliferator-activated receptor gamma polymorphisms with inflammatory bowel disease in a Hungarian cohort. **2012**, 18, 472-9		12
193	Rosiglitazone and Gemcitabine in combination reduces immune suppression and modulates T cell populations in pancreatic cancer. **2013**, 62, 225-36		50
192	Peroxisome Proliferator-Activated Receptors. **2013**,		4
191	Pathway hunting by random survival forests. **2013**, 29, 99-105		27
190	Interplay between SOX9, catenin and PPAR activation in colorectal cancer. **2013**, 1833, 1853-65		33
189	Tissue Distribution and Versatile Functions of PPARs. **2013**, 33-69		
188	SERPINA3K induces apoptosis in human colorectal cancer cells via activating the Fas/FasL/caspase-8 signaling pathway. **2013**, 280, 3244-55		23
187	The 5-aminosalicylic acid antineoplastic effect in the intestine is mediated by PPAR **2013**, 34, 2580-6		24
186	Deficiency of caveolin-1 in Apc(min/+) mice promotes colorectal tumorigenesis. **2013**, 34, 2109-18		24
185	Use of thiazolidinediones and the risk of colorectal cancer in patients with diabetes: a nationwide, population-based, case-control study. **2013**, 36, 369-75		28
184	Genetic variation in the inflammation and innate immunity pathways and colorectal cancer risk. **2013**, 22, 2094-101		15
183	Compartment-specific activation of PPAR governs breast cancer tumor growth, via metabolic reprogramming and symbiosis. **2013**, 12, 1360-70		23
182	Cyclooxygenase-2 expression in the tumor environment is associated with poor prognosis in colorectal cancer patients. **2013**, 6, 733-739		17
181	Antioxidant properties of mesalamine in colitis inhibit phosphoinositide 3-kinase signaling in progenitor cells. **2013**, 19, 2051-60		16
180	Molecular signatures of basal cell carcinoma susceptibility and pathogenesis: a genomic approach. **2013**, 42, 583-96		12
179	Emerging roles of peroxisome proliferator-activated receptor gamma in cancer. 392-402		
178	Autonomous inhibition of apoptosis correlates with responsiveness of colon carcinoma cell lines to ciglitazone. *PLoS ONE*, **2014**, 9, e114158	3.7	3

177	Therapeutic Implications of Black Seed and Its Constituent Thymoquinone in the Prevention of Cancer through Inactivation and Activation of Molecular Pathways. **2014**, 2014, 724658		65
176	Chemopreventive drugs: mechanisms via inhibition of cancer stem cells in colorectal cancer. *World Journal of Gastroenterology*, **2014**, 20, 3835-46	5.6	12
175	Pioglitazone inhibits the proliferation and metastasis of human pancreatic cancer cells. **2014**, 8, 2709-2714		27
174	Antiproliferative and apoptotic effects of telmisartan in human colon cancer cells. **2014**, 8, 2681-2686		23
173	A role for peroxisome proliferator-activated receptor gamma in resveratrol-induced colon cancer cell apoptosis. **2014**, 58, 1785-94		21
172	Luteolin potentiates the sensitivity of colorectal cancer cell lines to oxaliplatin through the PPARγ/OCTN2 pathway. **2014**, 25, 1016-27		19
171	Nonsteroidal anti-inflammatory drugs suppress cancer stem cells via inhibiting PTGS2 (cyclooxygenase 2) and NOTCH/HES1 and activating PPARG in colorectal cancer. **2014**, 134, 519-29		70
170	Cladosporol A, a new peroxisome proliferator-activated receptor γ (PPARγ) ligand, inhibits colorectal cancer cells proliferation through β-catenin/TCF pathway inactivation. **2014**, 1840, 2361-72		18
169	Attenuation of IFN-γ-induced B7-H1 expression by 15-deoxy-delta(12,14)-prostaglandin J2 via downregulation of the Jak/STAT/IRF-1 signaling pathway. **2014**, 112, 82-9		16
168	Small molecule agonists of PPAR-γ exert therapeutic effects in esophageal cancer. **2014**, 74, 575-85		40
167	A comparison and catalog of intrinsic tumor growth models. **2014**, 76, 2010-24		71
166	The combinatory effects of PPAR-γ agonist and survivin inhibition on the cancer stem-like phenotype and cell proliferation in bladder cancer cells. **2014**, 34, 262-8		18
165	Keap1/Nrf2 pathway in the frontiers of cancer and non-cancer cell metabolism. **2015**, 43, 639-44		47
164	Exploring Different Strategies for Efficient Delivery of Colorectal Cancer Therapy. *International Journal of Molecular Sciences*, **2015**, 16, 26936-52	6.3	27
163	The role of PPARβ/δ-mediated signalling in skin biology and pathology: new targets and opportunities for clinical dermatology. **2015**, 24, 245-51		50
162	Elevation of miR-27b by HPV16 E7 inhibits PPARγ expression and promotes proliferation and invasion in cervical carcinoma cells. **2015**, 47, 1759-66		37
161	A novel treatment strategy for glioblastoma multiforme and glioma associated seizures: increasing glutamate uptake with PPARγ agonists. **2015**, 22, 21-8		9
160	Recruited metastasis suppressor NM23-H2 attenuates expression and activity of peroxisome proliferator-activated receptor γ (PPARγ) in human cholangiocarcinoma. **2015**, 47, 62-7		6

159	Metabolic transformation of breast cancer in a MCF-7 xenograft mouse model and inhibitory effect of volatile oil from Saussurea lappa Decne treatment. **2015**, 11, 636-656	23
158	Protective Effects of Turbinaria ornata and Padina pavonia against Azoxymethane-Induced Colon Carcinogenesis through Modulation of PPAR Gamma, NF-B and Oxidative Stress. **2015**, 29, 737-48	18
157	Immunology and Immunotherapy of Ovarian Cancer. **2015**, 413-456	
156	Pioglitazone hydrochloride: chemopreventive potential and development of site-specific drug delivery systems. **2015**, 22, 408-17	2
155	PPAR Gamma in Neuroblastoma: The Translational Perspectives of Hypoglycemic Drugs. **2016**, 2016, 3038164	11
154	Computational Identification of Key Regulators in Two Different Colorectal Cancer Cell Lines. **2016**, 7, 42	7
153	Troglitazone Enhances the Apoptotic Response of DLD-1 Colon Cancer Cells to Photodynamic Therapy. **2016**, 57, 1494-9	6
152	The antiproliferative and proapoptotic effects of cladosporols A and B are related to their different binding mode as PPAR ligands. **2016**, 108, 22-35	18
151	Transcriptional Regulation of Human Cytosolic Sulfotransferase 1C3 by Peroxisome Proliferator-Activated Receptor In LS180 Human Colorectal Adenocarcinoma Cells. **2016**, 90, 562-569	4
150	Isoliquiritigenin suppresses tumor necrosis factor- nduced inflammation via peroxisome proliferator-activated receptor- n intestinal epithelial cells. **2016**, 39, 1465-1471	10
149	Pioglitazone inhibits EGFR/MDM2 signaling-mediated PPAR degradation. **2016**, 791, 316-321	8
148	The arachidonic acid metabolite 11 ProstaglandinF2 controls intestinal epithelial healing: deficiency in patients with Crohn s disease. **2016**, 6, 25203	21
147	Colorectal cancer risk genes are functionally enriched in regulatory pathways. **2016**, 6, 25347	3
146	Orphan drug development for targeting chronic myeloid leukemia stem cells. **2016**, 4, 837-843	1
145	EGFR/MDM2 signaling promotes NF-B activation via PPAR degradation. **2016**, 37, 215-222	15
144	Macrophage polarization: the link between inflammation and related diseases. **2016**, 65, 1-11	89
143	Optimization of anticancer exopolysaccharide production from probiotic Lactobacillus acidophilus by response surface methodology. **2016**, 46, 288-97	24
142	Transcriptomic dynamics of breast cancer progression in the MMTV-PyMT mouse model. **2017**, 18, 185	23

141	Commensal gut bacteria modulate phosphorylation-dependent PPARγ transcriptional activity in human intestinal epithelial cells. **2017**, 7, 43199		47
140	Cancer reversion, a renewed challenge in systems biology. **2017**, 2, 49-58		9
139	Thermodynamics in cancers: opposing interactions between PPAR gamma and the canonical WNT/beta-catenin pathway. **2017**, 6, 14		48
138	New insights into antidiabetic drugs: Possible applications in cancer treatment. **2017**, 90, 1056-1066		29
137	New diphenylmethane derivatives as peroxisome proliferator-activated receptor alpha/gamma dual agonists endowed with anti-proliferative effects and mitochondrial activity. **2017**, 127, 379-397		14
136	Identification of prostate cancer hub genes and therapeutic agents using bioinformatics approach. **2017**, 20, 553-561		15
135	Dose-response effects of aerobic exercise on body composition among colon cancer survivors: a randomised controlled trial. **2017**, 117, 1614-1620		23
134	Retinoic Acid affects Lung Adenocarcinoma growth by inducing differentiation via GATA6 activation and EGFR and Wnt inhibition. **2017**, 7, 4770		18
133	Quantitative evaluation and reversion analysis of the attractor landscapes of an intracellular regulatory network for colorectal cancer. **2017**, 11, 45		9
132	Therapeutic Potential and Pharmaceutical Development of Thymoquinone: A Multitargeted Molecule of Natural Origin. **2017**, 8, 656		96
131	Detecting Disease Specific Pathway Substructures through an Integrated Systems Biology Approach. **2017**, 3,		18
130	A marine bio-functional lipid, fucoxanthinol, attenuates human colorectal cancer stem-like cell tumorigenicity and sphere formation. **2017**, 61, 25-32		21
129	PPAR-γ Agonists As Antineoplastic Agents in Cancers with Dysregulated IGF Axis. *Frontiers in Endocrinology*, **2017**, 8, 31	5.7	53
128	Interactions between PPAR Gamma and the Canonical Wnt/Beta-Catenin Pathway in Type 2 Diabetes and Colon Cancer. **2017**, 2017, 5879090		60
127	In vitro and in vivo cytotoxicity of troglitazone in pancreatic cancer. **2017**, 36, 91		14
126	Reprogramming induced by isoliquiritigenin diminishes melanoma cachexia through mTORC2-AKT-GSK3β signaling. *Oncotarget*, **2017**, 8, 34565-34575	3.3	15
125	Lipid pathway deregulation in advanced prostate cancer. **2018**, 131, 177-184		44
124	Development of Preclinical Models to Understand and Treat Colorectal Cancer. **2018**, 31, 199-204		6

123	DKK2 imparts tumor immunity evasion through β-catenin-independent suppression of cytotoxic immune-cell activation. *Nature Medicine*, **2018**, 24, 262-270	50.5	76
122	Peroxisome proliferator-activated receptor γ coactivator-1α as a predictor of lymph node metastasis and poor prognosis in human colorectal cancer. **2018**, 33, 11-16		9
121	Peroxisome proliferator-activated receptor-γ agonist-mediated inhibition of cell growth is independent of apoptosis in human epidermoid carcinoma A431 cells. **2018**, 15, 6578-6584		4
120	PPARγ-Mediated p21 Induction in Aerodigestive Preneoplastic Cell Lines. **2018**, 127, 677-686		5
119	-Catenin Regulation in Sporadic Colorectal Carcinogenesis: Not as Simple as APC. **2018**, 2018, 4379673		4
118	Peroxisome Proliferator-Activated Receptor and PGC-1 in Cancer: Dual Actions as Tumor Promoter and Suppressor. **2018**, 2018, 6727421		34
117	Colon Cancer Chemoresistance and Chemosensitization. **2018**, 181-226		
116	Surface Functionalization and Targeting Strategies of Liposomes in Solid Tumor Therapy: A Review. *International Journal of Molecular Sciences*, **2018**, 19,	6.3	230
115	Relationship of , , and polymorphisms with susceptibility to hepatocellular carcinoma in an eastern Chinese Han population. **2018**, 11, 4651-4660		7
114	Biomarker targeting of colorectal cancer stem cells. **2019**, 13, 891-894		2
113	Activation and Expression of Peroxisome Proliferator-Activated Receptor Alpha Are Associated with Tumorigenesis in Colorectal Carcinoma. **2019**, 2019, 7486727		10
112	Mechanistic Investigation of the Androgen Receptor DNA-Binding Domain Inhibitor Pyrvinium. **2019**, 4, 2472-2481		6
111	Therapeutic targeting of gastrointestinal cancer stem cells. **2019**, 14, 331-343		5
110	Red meat intake, CYP2E1 and PPARγ polymorphisms, and colorectal cancer risk. **2019**, 28, 304-310		3
109	rs3856806 C>T Polymorphism Increased the Risk of Colorectal Cancer: A Case-Control Study in Eastern Chinese Han Population. *Frontiers in Oncology*, **2019**, 9, 63	5.3	15
108	A LITERATURE REVIEW ON ORAL HYPOGLYCEMIC DRUGS – MECHANISTIC ASPECTS. **2019**, 5-10		2
107	Telmisartan Influences the Antiproliferative Activity of Linoleic Acid in Human Colon Cancer Cells. **2020**, 72, 98-109		5
106	Peroxisome proliferator-activated receptor gamma controls prostate cancer cell growth through AR-dependent and independent mechanisms. **2020**, 80, 162-172		6

105	Falcarindiol Purified From Carrots Leads to Elevated Levels of Lipid Droplets and Upregulation of Peroxisome Proliferator-Activated Receptor-Gene Expression in Cellular Models. **2020**, 11, 565524		2
104	PRMT1 inhibition induces differentiation of colon cancer cells. **2020**, 10, 20030		5
103	Identification of an irreversible PPARantagonist with potent anticancer activity. **2020**, 8, e00693		5
102	Triglyceride-glucose index (TyG index) is a predictor of incident colorectal cancer: a population-based longitudinal study. **2020**, 20, 113		7
101	Ischemia reperfusion-induced metastasis is resistant to PPARagonist pioglitazone in a murine model of colon cancer. **2020**, 10, 18565		
100	The PPARAgonist Rosiglitazone Enhances the Radiosensitivity of Human Pancreatic Cancer Cells. **2020**, 14, 3099-3110		3
99	Pharmacological (or Synthetic) and Nutritional Agonists of PPAR-as Candidates for Cytokine Storm Modulation in COVID-19 Disease. *Molecules*, **2020**, 25,	4.8	63
98	Peroxisome Proliferator-Activated Receptors: Experimental Targeting for the Treatment of Inflammatory Bowel Diseases. **2020**, 11, 730		27
97	Troglitazone, a Selective Ligand for PPARInduces Cell-cycle Arrest in Human Oral SCC Cells. **2020**, 40, 1247-1254		7
96	PPAR-Mediated Toxicology and Applied Pharmacology. *Cells*, **2020**, 9,	7.9	30
95	Interaction of epidermal growth factor with COX-2 products and peroxisome proliferator-activated receptor-system in experimental rat Barrett's esophagus. *American Journal of Physiology - Renal Physiology*, **2020**, 318, G375-G389	5.1	2
94	Targeting PPAR ligands as possible approaches for metabolic reprogramming of T cells in cancer immunotherapy. *Immunology Letters*, **2020**, 220, 32-37	4.1	4
93	Redifferentiation therapeutic strategies in cancer. *Drug Discovery Today*, **2020**, 25, 731-738	8.8	6
92	Triorganotin complexes in cancer chemotherapy: Mechanistic insights and future perspectives. *Applied Organometallic Chemistry*, **2021**, 35, e6089	3.1	4
91	Abscisic acid regulates dormancy of prostate cancer disseminated tumor cells in the bone marrow. *Neoplasia*, **2021**, 23, 102-111	6.4	5
90	PPARgamma in Metabolism, Immunity, and Cancer: Unified and Diverse Mechanisms of Action. *Frontiers in Endocrinology*, **2021**, 12, 624112	5.7	41
89	Combined COX-2/PPARExpression as Independent Negative Prognosticator for Vulvar Cancer Patients. *Diagnostics*, **2021**, 11,	3.8	1
88	PPARs and Tumor Microenvironment: The Emerging Roles of the Metabolic Master Regulators in Tumor Stromal-Epithelial Crosstalk and Carcinogenesis. *Cancers*, **2021**, 13,	6.6	5

87	PPAR? drives IL-33-dependent ILC2 pro-tumoral functions. *Nature Communications*, **2021**, 12, 2538	17.4	7
86	Transcription Factors: The Fulcrum Between Cell Development and Carcinogenesis. *Frontiers in Oncology*, **2021**, 11, 681377	5.3	5
85	Rosuvastatin alleviated the liver ischemia reperfusion injury by activating the expression of peroxisome proliferator-activated receptor gamma (PPAR). *Journal of Bioenergetics and Biomembranes*, **2021**, 53, 573-583	3.7	0
84	Epigenetic derepression converts PPARinto a druggable target in triple-negative and endocrine-resistant breast cancers. *Cell Death Discovery*, **2021**, 7, 265	6.9	1
83	Thiazolidinediones as PPAR Agonists.		1
82	Molecular events in follicular thyroid tumors. *Cancer Treatment and Research*, **2004**, 122, 85-105	3.5	33
81	Abnormalities of nuclear receptors in thyroid cancer. *Cancer Treatment and Research*, **2004**, 122, 165-78	3.5	3
80	Transcriptional Regulation of Lipogenesis as a Therapeutic Target for Cancer Treatment. *Cancer Drug Discovery and Development*, **2014**, 259-275	0.3	1
79	Immune Modulation and Cancer Resistance. **2008**, 285-307		1
78	Possible Mechanisms of B PUFA Anti-tumour Action. **2010**, 3-38		5
77	Ligand activation of peroxisome proliferator-activated receptor induces apoptosis of leukemia cells by down-regulating the c-myc gene expression via blockade of the Tcf-4 activity.		5
76	The biologic basis for the use of retinoids in cancer prevention and treatment. *Current Opinion in Oncology*, **1999**, 11, 497-502	4.2	25
75	Peroxisome proliferator-activated receptors: mediators of a fast food impact on gene regulation. *Current Opinion in Clinical Nutrition and Metabolic Care*, **1999**, 2, 307-12	3.8	5
74	Transcriptional regulation of adipogenesis. *Genes and Development*, **2000**, 14, 1293-1307	12.6	1088
73	PPARligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. *Journal of Clinical Investigation*, **2002**, 110, 923-932	15.9	237
72	PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. *Journal of Clinical Investigation*, **2002**, 110, 923-32	15.9	145
71	PPAR-gamma receptor ligands: novel therapy for pituitary adenomas. *Journal of Clinical Investigation*, **2003**, 111, 1381-8	15.9	55
70	PPAR-receptor ligands: novel therapy for pituitary adenomas. *Journal of Clinical Investigation*, **2003**, 111, 1381-1388	15.9	116

69	Mitogen-activated protein kinase inhibits 1,25-dihydroxyvitamin D3-dependent signal transduction by phosphorylating human retinoid X receptor alpha. *Journal of Clinical Investigation*, **1999**, 103, 1729-35	15.9	117
68	A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. *Journal of Clinical Investigation*, **1999**, 104, 383-9	15.9	602
67	Hepatocyte nuclear factor 1 suppresses steatosis-associated liver cancer by inhibiting PPAR transcription. *Journal of Clinical Investigation*, **2017**, 127, 1873-1888	15.9	35
66	15-deoxy-delta(12,14)-PGJ(2) induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats. *Journal of Clinical Investigation*, **2000**, 106, 189-97	15.9	311
65	The role of PPARs in inflammation and immunity. **2002**, 71, 388-400		63
64	The peroxisome proliferator-activated receptor is an inhibitor of ErbBs activity in human breast cancer cells. *Journal of Cell Science*, **2001**, 114, 4117-4126	5.3	34
63	Effect of Proliferator-Activated Receptor- Pro12Ala Polymorphism on Colorectal Cancer Risk: A Meta-Analysis. *Medical Science Monitor*, **2015**, 21, 1611-6	3.2	9
62	Inhibition of oxidative stress-elicited AKT activation facilitates PPAR agonist-mediated inhibition of stem cell character and tumor growth of liver cancer cells. *PLoS ONE*, **2013**, 8, e73038	3.7	25
61	Anticancer activities of pterostilbene-isothiocyanate conjugate in breast cancer cells: involvement of PPAR *PLoS ONE*, **2014**, 9, e104592	3.7	19
60	Loss of PTEN Facilitates Rosiglitazone-Mediated Enhancement of Platinum(IV) Complex LA-12-Induced Apoptosis in Colon Cancer Cells. *PLoS ONE*, **2015**, 10, e0141020	3.7	3
59	PPARG expression in colorectal cancer and its association with staging and clinical evolution. *Acta Cirurgica Brasileira*, **2020**, 35, e202000708	1.6	2
58	KRAS mutant colorectal cancer gene signatures identified angiotensin II receptor blockers as potential therapies. *Oncotarget*, **2017**, 8, 3206-3225	3.3	7
57	PPAR activation by troglitazone enhances human lung cancer cells to TRAIL-induced apoptosis via autophagy flux. *Oncotarget*, **2017**, 8, 26819-26831	3.3	16
56	Association of rs 1801282 C>G polymorphism with risk of colorectal cancer: from a case-control study to a meta-analysis. *Oncotarget*, **2017**, 8, 100558-100569	3.3	6
55	The peroxisome proliferator activated receptor gamma agonist pioglitazone increases functional expression of the glutamate transporter excitatory amino acid transporter 2 (EAAT2) in human glioblastoma cells. *Oncotarget*, **2015**, 6, 21301-14	3.3	20
54	Solid tumor differentiation therapy - is it possible?. *Oncotarget*, **2012**, 3, 559-67	3.3	73
53	Ginger: A Novel Strategy to Battle Cancer through Modulating Cell Signalling Pathways: A Review. *Current Pharmaceutical Biotechnology*, **2019**, 20, 5-16	2.6	16
52	Significance of LRP and PPAR-gamma Expression in Lipomatous Soft Tissue Tumors. *The Open Orthopaedics Journal*, **2010**, 4, 48-55	0.3	3

51	The multifaceted role of curcumin in cancer prevention and treatment. *Molecules*, **2015**, 20, 2728-69	4.8	283
50	Curcumin suppresses PPARdelta expression and related genes in HT-29 cells. *World Journal of Gastroenterology*, **2009**, 15, 1346-52	5.6	20
49	Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. *World Journal of Gastroenterology*, **2009**, 15, 310-20	5.6	21
48	Peroxisome proliferator-activated receptor-gamma is essential in the pathogenesis of gastric carcinoma. *World Journal of Gastroenterology*, **2009**, 15, 3874-83	5.6	14
47	Antidiabetic thiazolidinediones induce ductal differentiation but not apoptosis in pancreatic cancer cells. *World Journal of Gastroenterology*, **2005**, 11, 1122-30	5.6	20
46	Effect of ligand troglitazone on peroxisome proliferator-activated receptor gamma expression and cellular growth in human colon cancer cells. *World Journal of Gastroenterology*, **2006**, 12, 7263-70	5.6	9
45	Bitter gourd (Momordica charantia): a potential mechanism in anti-carcinogenesis of colon. *World Journal of Gastroenterology*, **2007**, 13, 1761-2	5.6	2
44	15d-PGJ2 inhibits cell growth and induces apoptosis of MCG-803 human gastric cancer cell line. *World Journal of Gastroenterology*, **2003**, 9, 2149-53	5.6	34
43	Peroxisome proliferator-activated receptor gamma ligands inhibit cell growth and induce apoptosis in human liver cancer BEL-7402 cells. *World Journal of Gastroenterology*, **2003**, 9, 1683-8	5.6	28
42	The role of peroxisome proliferator-activated receptor gamma in prostate cancer. *Asian Journal of Andrology*, **2018**, 20, 238-243	2.8	27
41	Thiazolidinediones and risk of colorectal cancer in patients with diabetes mellitus: A meta-analysis. *Saudi Journal of Gastroenterology*, **2018**, 24, 75-81	3	12
40	Peroxisome proliferator-activated receptor □and colorectal cancer. *World Journal of Gastrointestinal Oncology*, **2010**, 2, 159-64	3.4	33
39	Peroxisome proliferator activated receptor-□and the ubiquitin-proteasome system in colorectal cancer. *World Journal of Gastrointestinal Oncology*, **2010**, 2, 235-41	3.4	5
38	STAT3 as a Potential Target for Tumor Suppressive Effects of 15-Deoxy-□prostaglandin J in Triple Negative Breast Cancer. *Journal of Cancer Prevention*, **2021**, 26, 207-217	3	0
37	Peroxisome Proliferator-Activated Receptors. **2001**, 363-388		
36	PPAR□Ligand and Induction of Growth Arrest in Pancreatic Cancer Cells. **2001**, 132-137		
35	Regulation of the Cell Cycle by Peroxisome Proliferator □Activated Receptor Gamma (PPAR□) **2002**, 191-205		0
34	Involvement of p21WAF1/CIP1 and p27KIP1 in Troglitazone-Induced Cell Cycle Arrest in Human Hepatoma Cell Lines. **2002**, 61-72		

33	Kolorektales Karzinom. **2002**, 231-256		
32	Multi-site therapeutic modalities for inflammatory bowel diseases mechanisms of action. **2003**, 523-551		
31	Negative Regulation of the Basophil Activation by Natural Ligands for Peroxisome Proliferator-Activated Receptors. **2003**, 369-374		
30	An Overview of Mechanistic Toxicogenomic Studies. **2003**,		
29	The role of peroxisome proliferator-activated receptor gamma in colon cancer and inflammatory bowel disease. *Archives of Pathology and Laboratory Medicine*, **2003**, 127, 1121-3	5	29
28	Immunomodulation by Fish Oil Derived Polyunsaturated Fatty Acids in Cancer. **2010**, 173-195		
27	The Impact of Inflammation Control and Active Cancer Palliation on Metabolic Pathways Determining Tumor Progression and Patient Survival. **2010**, 313-340		
26	The Impact of Redox State on Regulation of the High-Affinity IgE Receptor Expression. **2010**, 259-264		
25	Expression of Cyclooxygenase-1, -2, Peroxisome Proliferator-activated Receptor gamma in Human Colorectal Carcinoma.. *Annals of Cancer Research and Therapy*, **2010**, 18, 6-12	0.2	
24	Obesity, Type 2 Diabetes and Cancer. **2012**, 37-72		
23	The Development and Use of Genetically Tractable Preclinical Mouse Models. **2012**, 477-495		1
22	The Pro115Gln Missense Mutation of Peroxisome Proliferator Activated Receptor (PPAR) Gene in Diabetes in the Pakistani Population. *Avicenna Journal of Clinical Microbiology and Infection*, **2016**, 3, 35148-35148	0.3	0
21	Therapeutic role of metformin and troglitazone to prevent cancer risk in diabetic patients: evidences from experimental studies. *Turkish Journal of Biochemistry*, **2020**, 45, 229-239	0.3	
20	Role of treatments for diabetes and hyperlipidaemia in risk and mortality of primary and secondary brain tumours.		
19	Immunology and Immunotherapy of Ovarian Cancer. **2020**, 487-540		
18	PPAR Agonists in Combination Cancer Therapies. *Current Cancer Drug Targets*, **2020**, 20, 197-215	2.8	3
17	Englitazone Delays Fetal Growth in Late Gestation in the Rat. **2005**, 480-486		
16	Epithelial Ovarian Cancer. **2005**, 473-486		

15	Peroxisome-proliferator-activated receptor delta mediates the effects of long-chain fatty acids on post-confluent cell proliferation. *Biochemical Journal*, **2000**, 350 Pt 1, 93-8	3.8	13
14	Gene alterations by peroxisome proliferator-activated receptor gamma agonists in human colorectal cancer cells. *International Journal of Oncology*, **2008**, 32, 809-19	1	12
13	Nuclear receptor agonists as potential differentiation therapy agents for human osteosarcoma. *Clinical Cancer Research*, **2002**, 8, 1288-94	12.9	67
12	Effects of Dietary Polyunsaturated Fatty Acids on DNA Methylation and the Expression of and Genes in Rats. *Avicenna Journal of Medical Biotechnology*, **2018**, 10, 214-219	1.4	6
11	NSAIDs and Cancer Resolution: New Paradigms beyond Cyclooxygenase.. *International Journal of Molecular Sciences*, **2022**, 23,	6.3	5
10	Epigenetics of Cutaneous T-Cell Lymphomas.. *International Journal of Molecular Sciences*, **2022**, 23,	6.3	0
9	Overexpression of the PPAR-protein in primary Ta/T1 non-muscle-invasive urothelial carcinoma.. *Molecular and Clinical Oncology*, **2022**, 16, 36	1.6	0
8	Table_1.docx. **2019**,		
7	A new class of peroxisome proliferator-activated receptor [PPAR]agonists that inhibit growth of breast cancer cells: 1,1-Bis(3?-indolyl)-1-(p-substituted phenyl)methanes. *Molecular Cancer Therapeutics*, **2004**, 3, 247-260	6.1	24
6	Peroxisome Proliferator-Activated Receptors and the Hallmarks of Cancer. **2022**, 11, 2432		2
5	Engaging plasticity: Differentiation therapy in solid tumors. 13,		0
4	TRIB3 Modulates PPARMediated Growth Inhibition by Interfering with the MLL Complex in Breast Cancer Cells. **2022**, 23, 10535		0
3	Terminal differentiation and anti-tumorigenic effects of prolactin in breast cancer. 13,		0
2	UCP2 as a Cancer Target through Energy Metabolism and Oxidative Stress Control. **2022**, 23, 15077		0
1	Inflammation-Related Signature Profile Expression as a Poor Prognosis Marker after Oxaliplatin Treatment in Colorectal Cancer. **2023**, 24, 3821		1